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incidence	 and	mortality,	 and	 is	 disproportionately	 prevalent	 in	 developing	 nations	
due	to	a	lack	of	adequate	access	to	healthcare.	While	new	vaccine	technologies	are	





driver	of	oncogenesis	 in	 cervical	 cancers	 and	has	been	 shown	 to	exacerbate	 some	
aspects	 of	 cervical	 cancers.	 While	 some	 of	 the	 cellular	 signaling	 pathways	
responsible	 for	 these	 phenomena	 have	 been	 identified,	 much	 remains	 to	 be	
elucidated.	 We	 hypothesized	 that	 TBX2	 and	 TBX3,	 two	 highly	 homologous	
transcription	factors	frequently	 implicated	in	other	cancers,	may	be	responsible	for	




cancer	 cell	 lines.	 Furthermore,	 SF	 upregulated	 TBX3	 protein	 expression	 in	 both	 of	


















Cervical	 cancer	 refers	 to	 cancer	 of	 the	uterine	 cervix,	which	 forms	 the	part	 of	 the	




easily	 identified,	 thus	 making	 screening	 programs	 very	 effective	 preventative	




the	 developing	 world,	 where	 cervical	 cancers	 will	 continue	 to	 occur	 with	 great	
frequency.	 The	 biochemical	 processes	 driving	 cervical	 cancer	 formation	 and	
progression	 are	 not	 yet	 fully	 elucidated	 despite	 intensive	 study	 and	 the	 primary	
causative	agent	being	known.	This	has	resulted	in	a	lack	of	effective	approaches	for	
treating	 cervical	 cancers	 and	 therefore	while	 cervical	 cancer	 is	 highly	 preventable,	
treatment	 success	 rates	 remain	 poor.	 Research	 focusing	 on	 the	 molecular	
underpinnings	of	the	disease	must	be	conducted	so	that	targeted	therapies	can	be	





Globally,	 cervical	 cancer	 is	 the	 fourth	most	 common	 female	 cancer	and	 the	 fourth	
most	 common	 cause	 of	 female	 cancer	 death	 (Stewart	 &	Wild,	 2014).	 In	 2012,	 an	
estimated	528	000	new	cases	(7.9%	of	all	female	cancers)	and	266	000	(7.5%)	deaths	
occurred	 due	 to	 cervical	 cancer	 (Ferlay	 et	 al.,	 2015).	 The	 disease	 imposes	 a	
disproportionate	 burden	 on	 the	 developing	 world	 as	 it	 occurs	 most	 commonly	 in	
3	
developing	nations	(Plummer	et	al.,	2016).	It	is	the	second	most	common	cancer	in	
developing	 regions	while	 only	 being	 the	 11
th
	most	 common	 in	 developed	 regions.	
Furthermore,	 87%	 of	 deaths	 occur	 in	 less	 developed	 regions	 (Ferlay	 et	 al.,	 2015).	
These	 disparities	 are	 largely	 due	 to	 the	 prevention	 and	 early	 detection	 of	 disease	
afforded	by	well-implemented	screening	procedures	and	medical	care	in	developed	
nations	or	in	nations	with	advanced	healthcare	infrastructure.	In	the	United	States	of	
America,	 for	 instance,	 cervical	 cancer	 incidence	 has	 decreased	 by	more	 than	 80%	
between	1930-2012,	 largely	 due	 to	 improved	 screening	programs	 (Siegel,	Miller	&	
Jemal,	2016).	Similarly,	the	5-year	net	survival	rate	for	cervical	cancer	varies	widely	
around	the	world.	Across	61	countries	for	which	data	were	available	to	calculate	the	
age-standardized	 5-year	 net	 survival	 of	 women	 diagnosed	 in	 2005-2009,	 ≥70%	
survival	was	seen	in	the	top	four	countries,	60-69%	in	31	others,	50-59%	in	26,	and	
<50%	 in	 the	bottom	 two.	Developing	 countries	 are	disproportionately	prevalent	 in	
the	lower	half	of	the	distribution	of	survival	rates	(Allemani	et	al.,	2015).		
1.1.2. Anatomical	origin	and	major	types	of	cervical	cancer	
Cervical	 cancer	 most	 often	 originates	 at	 the	 transformation	 zone	 of	 the	 cervix,	
wherein	the	 interface	between	the	columnar	epithelium	of	the	endocervix	and	the	




Three	 major	 types	 of	 cervical	 cancer	 exist;	 squamous	 cell	 carcinomas,	
adenocarcinomas,	and	other	undifferentiated	carcinomas.	Squamous	cell	carcinomas	
are	the	most	common,	accounting	for	85-90%	of	all	cases.	Adenocarcinoma	variants,	





HPVs	 are	 a	 family	 of	 non-enveloped	 DNA	 viruses	 consisting	 of	 relatively	 small,	
double-stranded	 circular	 genomes	 (~8000	 base	 pairs)	 encoding	 8-9	 open	 reading	
frames.	 While	 the	 total	 gene	 number	 is	 low,	 the	 number	 of	 encoded	 proteins	 is	
much	 greater	 due	 to	 transcription	 from	 multiple	 promoter	 regions	 as	 well	 as	
complex	 transcriptional	 splicing	 patterns.	 These	 genomes	 are	 encapsulated	 in	
icosahedral	 capsids	 consisting	 of	 360	 L1	 capsid	 proteins	 arranged	 into	 72	
capsomeres,	 which	 assemble	with	 one	 another	 and	with	 a	 variable	 number	 of	 L2	
capsid	proteins	 (Doorbar	et	al.,	 2016).	 It	 is	 the	most	 common	sexually	 transmitted	




number	 of	 other	 cancers	 such	 as	 penile,	 prostate,	 anal,	 vulvar,	 vaginal,	 and	
oropharyngeal	 carcinomas	 (Yang	 et	 al.,	 2015;	 Plummer	 et	 al.,	 2016).	 Over	 150	
different	strains	of	HPV	have	been	described	and	13	high-risk	subtypes	(HPVs	16,	18,	
31,	 33,	 35,	 39,	 45,	 51,	 52,	 56,	 58,	 59	 and	 68)	 have	 been	 identified	 as	 being	





can	 be	 detected	 in	 essentially	 all	 cervical	 cancers.	 In	 the	 case	 of	 cervical	 cancers,	
HPV16	 and	 -18	 are	 the	 most	 carcinogenic	 subtypes,	 collectively	 causing	 ~70%	 of	
cervical	cancer	cases	(IARC,	2012).	However,	the	distribution	of	HPV	strains	detected	
in	 cervical	 carcinomas	 varies	 internationally.	 In	 the	 African	 context,	 HPV16	







invasive	 cervical	 cancer	within	 two	 decades	 (IARC,	 2012).	 During	 this	 process,	 the	
lesions	 follow	 a	 characteristic	 and	well-defined	 progression	 from	mild	 dysplasia	 to	
carcinoma	 (Figure	 1.1)(Stewart	 &	Wild,	 2014).	 Briefly,	 HPV	 is	 introduced	 into	 the	
female	reproductive	tract	through	sexual	 intercourse	with	an	 infected	partner.	 It	 is	
thought	 to	 travel	 through	micro-abrasions	 in	 the	 cervical	 epithelium	 to	 reach	 the	
basal	cell	layer	where	it	infects	basal	epithelial	cells.	The	Viral	DNA	is	then	amplified	
episomatically	using	 the	host	machinery.	High-risk	HPV	 types	 then	 rely	on	 their	E6	
and	 E7	 oncogenes	 to	 drive	 proliferation	 at	 the	 basal	 and	 parabasal	 layers.	 E7	
proteins	from	high-risk	subtypes	are	able	to	sequester	and	degrade	Retinoblastoma	
(Rb)	protein	 family	members	 such	as	p107,	which	 is	 responsible	 for	 regulating	 cell	
cycle	entry	at	the	basal	epithelium,	and	p130,	which	regulates	re-entry	in	the	upper	
epithelial	 layers.	 Rb	 regulates	 entry	 from	G1	 into	 S	 phase	 by	 inhibiting	 E2F	 family	
members,	 thus	effectively	preventing	aberrant	mitosis	 (Giacinti	&	Giordano,	2006).	
E7	 competes	with	 E2F	proteins	 for	 Rb	protein	binding	 and	 therefore	prevents	 E2F	
transcription	 factor	 family	 proteins	 from	 being	 inhibited.	 E2F	 in	 turn	 activates	 a	
number	of	other	genes	needed	for	S-phase	propagation	and	entry	into	the	cell	cycle.	
Normally,	 aberrant	 expression	 of	 these	 genes	 results	 in	 inactivation	 of	MDM	 and	
subsequent	p53	activation,	which	in	turn	results	in	cellular	senescence	or	apoptosis.	
In	high-risk	HPV-infected	cells,	however,	oncogenic	E6	proteins	associate	with	host	
machinery	 to	ubiquitinate	p53,	which	 leads	 to	 its	degradation	and	thus	prevents	 it	
from	countering	the	E7-induced	proliferation	(reviewed	in	Doorbar	et	al.,	2016).	As	
the	cells	proliferate,	the	normal	cervical	tissue	is	replaced	by	cervical	intraepithelial	
neoplasia	 (CIN),	which	 is	 graded	 into	 three	 grades.	 During	 this	 time	 the	 viral	 DNA	
integrates	 with	 the	 host	 genome	 and	 E6	 and	 E7	 expression	 increases	 with	 lesion	
severity.	At	its	most	extreme	(CIN3	or	carcinoma	in	situ),	neoplastic	cells	eventually	
disrupt	 the	 epithelial	 basement	membrane	 at	 which	 point	 a	 diagnosis	 of	 invasive	
carcinoma	is	made	(Stewart	&	Wild,	2014;	Doorbar	et	al.,	2016).	Recently,	a	subset	
of	 cervical	 cancers	 in	which	HPV	mRNA	 transcripts	were	 absent	 despite	 viral	 DNA	
being	present	in	the	genome	was	identified.	These	cancers	are	capable	of	sustaining	
themselves	 in	 the	 absence	 of	 viral	 E6	 and	 E7	 gene	 expression	 and	 exhibit	marked	





While	 HPV	 infection	 is	 a	 necessary	 cause	 for	 cervical	 carcinogenesis,	 it	 is	 not	
sufficient.	 Over	 90%	 of	 infections	 spontaneously	 regress	 1.5	 years	 post-infection	
(Castle	 et	 al.,	 2009).	 It	 is	 unclear	 why	 regression	 fails	 to	 occur	 in	 the	 remaining	









significantly	 more	 common	 in	 HIV+	 individuals	 relative	 to	 the	 general	 population	
(Grulich	 et	 al.,	 2007).	 Immunodeficiency	 caused	 by	 HIV	 infection	 seems	 to	 be	 the	
likely	 cause.	 Firstly,	 because	 immunosuppressed	 transplant	 patients	 also	 have	 a	
greater	 risk	 of	 developing	 cervical	 cancer	 (Grulich	 et	 al.,	 2007).	 Secondly,	 African	
HIV+	 women	 with	 cervical	 cancer	 exhibit	 different	 distributions	 of	 high-risk	 HPV	
strains	relative	to	HIV-	African	cervical	cancer	cases.	 	A	meta-analysis	by	Clifford	et	
al.	(2016)	found	that	while	the	rate	of	HPV16	and	-18	detection	is	similar	across	the	
two	 groups,	 HIV+	 patients	 exhibit	 significantly	 fewer	 single	 infections	with	HPV16,	
while	 co-infections	 of	 HPV16	 and	 other	 high	 risk	 HPVs	 is	 more	 likely.	 Conversely,	
HPV18	 single	 and	 co-infections	 are	 more	 common	 in	 HIV+	 women,	 and	 all	 other	
high-risk	types	were	more	common	as	part	of	co-infections	in	HIV+	women.		Owing	
to	the	fact	the	HPV16	prevalence	is	less	affected	by	CD4+	cell	counts	(Strickler	et	al.,	
2003),	 the	authors	 suggest	 that	HPV16	has	 adapted	more	efficient	mechanisms	 to	
evade	the	 immune	response,	 thus	 it	acquires	a	 lesser	benefit	 from	a	compromised	
immune	 system	 relative	 to	 the	other	high	 risk	 strains	 that	do	 show	an	 increase	 in	
prevalence	in	immunocompromised	women	(Clifford	et	al.,	2016).	
	
Some	 behavioural	 risk	 factors	 have	 been	 identified,	 but	 their	 relative	 impacts	 are	
much	 weaker	 than	 the	 risk	 of	 persistent	 HPV	 infection	 or	 HIV	 co-infection.	 Some	







Limited	 and	 contradictory	 evidence	 regarding	 the	 existence	 of	 genetic	
predispositions	 to	 developing	 cervical	 cancer	 exists.	 Genome-wide	 association	
studies	 on	 Chinese	 Han	 populations	 have	 identified	 genetic	 risk	 factors	 at	 3	 loci;	
4q12,	 17q12	 and	 6p21.32	 (Shi	et	 al.,	 2013).	 Conversely,	while	Nordic	 twin	 studies	
have	 identified	 relatively	 excessive	 familial	 risk	 factors	 for	 other	 cancers	 of	 the	
female	reproductive	tract,	no	such	risk	was	apparent	in	cervical	cancer	(Mucci	et	al.,	
8	




named	 the	 T-box	 have	 been	 identified	 across	 a	 wide	 spectrum	 of	 eukaryotic	
organisms	 (Sebé-Pedrós	 &	 Ruiz-Trillo,	 2017).	 Called	 the	 T-box	 family,	 each	 T-box	
transcription	 factor	 (TBX)	 binds	 to	 a	 canonical,	 palindromic	 core	DNA	 sequence	 in	
vitro	 (T(G/C)ACACCT	 AGGTGTGAAATT),	 also	 called	 the	 T-element	 (Kavka	 &	 Green,	
1997).	While	it	 is	generally	found	as	a	palindrome,	functional	half	sites	(TCACACCT)	
also	 exist	 (Fernando	 et	 al.,	 2010).	 Furthermore,	 T-box	 factors	 may	 also	 bind	 to	
variants	thereof	in	vivo	(Kispert	&	Herrmann,	1993;	Sinha	et	al.,	2000;	Bruneau	et	al.,	
2001;	 Lingbeek,	 Jacobs	&	Van	 Lohuizen,	 2002;	 Paxton	et	 al.,	 2002).	 This	 sequence	
variation	 gives	 rise	 to	 variance	 in	 the	 target	 genes	 regulated	by	 each	 T-box	 family	
member	 (Papaioannou,	 2014),	 possibly	 in	 conjunction	 with	 context-specific	
interactions	with	cofactors	(Lu	et	al.,	2010).		
More	 than	 20	 T-box	 family	 members	 have	 been	 discovered	 in	 humans.	 Their	








TBX2	 and	 TBX3	 are	 part	 of	 the	 Tbx2	 subfamily	 of	 T-box	 factors.	 Comprising	 TBX2,	
TBX3,	 TBX4,	 and	 TBX5,	 this	 subfamily	 is	 hypothesized	 to	 originate	 from	 a	 single	
9	
ancestral	gene,	with	unequal	crossing	over	events	resulting	 in	 two	clusters,	Tbx2/3	
and	 Tbx4/5,	 followed	 by	 a	 second	 event	 producing	 the	 four	 separate	 genes.	 In	
humans,	TBX2	and	TBX4	are	situated	on	chromosome	17q23,	while	TBX3	and	TBX5	
reside	on	12q24	(Campbell	et	al.,	1995;	Agulnik	et	al.,	1996;	Bamshad	et	al.,	1997).	
Despite	 their	 relatively	 distant	 chromosomal	 locations,	 TBX2	 and	 TBX3	 share	 the	













TBX3	 encodes	 two	 isoforms,	 TBX3	 and	 TBX3+2a.	 The	 transcripts	 span	 seven	 and	
eight	 exons	 and	 encode	 723	 and	 743	 amino	 acid	 proteins,	 respectively.	 TBX3+2a	
contains	an	additional	60bp	sequence	in	the	middle	of	the	T-box	that	adds	20	amino	




the	 authors	 speculate	 that	 it	 can	 also	 naturally	 bind	 target	 genes	 as	 a	 monomer	
through	the	half-site	of	the	palindromic	sequence.	Like	TBX2,	 it	also	possesses	two	
repression	 domains	 and	 an	 activation	 domain	 (Carlson	 et	 al.,	 2001).	 While	 TBX3	
predominantly	 acts	 as	 a	 repressor	 of	 transcription,	 recent	 findings	 have	 shown	





showed	 that	 the	 two	were	 variably	 expressed	 in	mature	 adult	 human	 and	mouse	
tissues	 and	 that	 TBX3	 can	 induce	 immortalisation	 of	 mouse	 embryo	 fibroblasts,	
whereas	 TBX3+2a	 accelerated	 senescence	 and	 could	 not	 bind	 DNA	 in	 their	 study.	
Both	 isoforms	 are	 highly	 expressed	 in	 mouse	 embryonic	 stem	 cells	 (mESCs)	 and	
induced	 pluripotent	 stem	 cells,	 where	 overexpression	 of	 either	 can	 induce	 mESC	
differentiation.	 However,	 while	 both	 isoforms	 repressed	 Nanog	 transcription,	 only	
TBX3+2a	 could	 do	 so	 directly	 (Zhao,	 Wu	 &	 Chen,	 2014).	 Conversely,	 work	 by	




and	 Nppa	 promoter	 activity.	 Furthermore,	 the	 authors	 showed	 that	 ectopic	
expression	 of	 either	 isoform	 repressed	 chamber	 formation	 in	 embryonic	 mouse	
hearts.	Both	isoforms	behave	similarly	to	promote	cancer	progression	in	a	model	of	
early	 breast	 cancer,	 and	 both	 behave	 similarly	 as	 tumour	 suppressors	 in	
fibrosarcoma	cells	(Krstic	et	al.,	2016;	Willmer,	Cooper,	et	al.,	2016).	Taken	together,	







a.	 The	 human	 TBX2	 and	 TBX3	mRNA	 genes.	 Exon	 and	 intron	 lengths	 are	 indicated.	 The	 additional	
60bp	 +2a	 segment	 found	 in	 the	 TBX3+2a	 isoform	 is	 boxed	 in	 red.	 Information	 was	 obtained	 and	
figures	 were	 adapted	 from	 Ensembl.org	 for	 transcripts	 ENST00000240328.3	 (TBX2),	
ENST00000349155.6	(TBX3)	and	ENST00000257566.7	(TBX3+2a).	b.	Diagrams	of	the	human	TBX2	and	
TBX3	proteins	depicting	identified	domain	regions.	Amino	acid	positions	are	indicated	at	boundaries	
between	regions.	The	additional	20	amino	acids	 in	TBX3+2a	are	 included	 in	the	TBX3	protein	at	the	
insert	 position	 (220-240)	 and	 indicated	 in	 blue,	 but	 subsequent	 amino	 acid	 position	 numberings	
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TBX2	 plays	 a	 significant	 role	 in	 limb,	 heart,	 eye,	 kidney,	 lung,	 melanocyte	 and	
mammary	gland	development	(Papaioannou,	2014;	Sheeba	&	Logan,	2017).	Murine	
homozygous	 Tbx2	 mutants	 spontaneously	 abort	 mid-gestation	 due	 to	 heart	
abnormalities	while	heterozygous	mutants	exhibit	normal	phenotypes	(Harrelson	et	
al.,	2004).	While	no	human	disorders	have	been	associated	with	TBX2,	studies	have	
associated	 microdeletions	 on	 chromosome	 17q23	 (where	 TBX2	 and	 TBX4	 reside)	
with	 an	 as	 yet	 unnamed	 syndrome	 that	 commonly	 features	 developmental	
retardation,	 microcephaly,	 heart,	 hand,	 foot	 and	 limb	 abnormalities	 as	 well	 as	
delayed	 postnatal	 growth	 (Ballif	 et	 al.,	 2010;	 Nimmakayalu	 et	 al.,	 2011;	 Willmer,	







et	 al.,	 2015).	 It	 has	 also	been	 shown	 to	promote	neuroepithelial	 differentiation	of	
human	embryonic	 stem	 cells,	 but	 not	 endoderm	development	 as	 it	 can	 also	 do	 in	
mice	 (Esmailpour	 &	 Huang,	 2012).	 TBX3	 acts	 during	 cardiac	 development,	
particularly	in	the	development	of	the	atrioventricular	canal,	the	ventricular	septum	
and	 the	 cardiac	 conduction	 system	 (Davenport,	 Jerome-Majewska	&	Papaioannou,	
2003;	Hoogaars	et	 al.,	 2007;	 Bakker	et	 al.,	 2012).	 It	 also	 plays	 a	 significant	 role	 in	
mammary	gland	development,	as	evidenced	by	the	higher	 incidence	of	deformities	
and	 aplasia	 observed	 in	 murine	 Tbx3	 heterozygous	 mutants	 (Davenport,	 Jerome-
Majewska	&	Papaioannou,	2003).	In	humans,	heterozygous	mutation	of	TBX3	results	
in	an	autosomal	dominant	development	disorder	 called	ulnar	mammary	 syndrome	







Recently,	 however,	 TBX3	 has	 been	 shown	 to	 also	 act	 as	 a	 regulator	 of	 alternative	
splicing	 of	 mRNA;	 TBX3	 mutants	 found	 in	 UMS	 were	 unable	 to	 direct	 alternative	
splicing	 to	 varying	 degrees,	 either	 due	 to	 disruption	 of	 the	 recruitment	 of	 RNA-








and	 progression	 of	 a	 number	 of	 different	 cancers.	 Despite	 the	 high	 degree	 of	
structural	 homology	 between	 the	 two,	 their	 roles	 in	 oncogenesis	 often	 do	 not	
overlap	 and	 both	 may	 play	 different	 roles	 depending	 on	 the	 cancer	 context.	
Furthermore,	evidence	is	accumulating	to	suggest	that	both	TBX2	and	TBX3	can	act	
as	 tumour	 suppressors	 in	 certain	 contexts.	 A	 comprehensive	 review	 of	 all	 of	 their	
oncogenic	 activities	 is	 beyond	 the	 scope	 of	 this	 work,	 and	 as	 such	 only	 areas	 of	

















TBX2’s	 significant	 pro-proliferative	 /	 anti-senescence	 roles	 are	 mediated	 by	
inactivation	 of	 the	 p14
ARF














often	 disabled	 in	 cancers,	 the	 influence	 of	 TBX2	 on	 p14
ARF




al.,	 2006).	 Indeed,	 silencing	 Tbx2	 expression	 in	 CDKN2A-null	 B16	 melanoma	 cells	
induces	senescence,	which	is	accompanied	by	increased	expression	of	p21	(Vance	et	
al.,	 2005).	 	 Similarly,	 TBX2	 mRNA	 expression	 was	 upregulated,	 and	 p21	
downregulated	in	an	inversely	correlative	manner,	in	a	study	on	laryngeal	squamous	
cell	 carcinomas	 relative	 to	 adjacent	 normal	 tissues.	 Patients	with	 high	 TBX2	 /	 low	
p21	 expressing	 cancers	 had	 a	 significantly	 lower	 chance	 of	 survival	 (Huang	 et	 al.,	
2014).	TBX2	also	reduces	p21	expression	in	rhabdomyosarcomas	where	it	functions	
to	 promote	 proliferation	 (Zhu	 et	 al.,	 2014).	 p21	 repression	 is	 enhanced	 by	
phosphorylation	 of	 TBX2	 in	 response	 to	 activation	 of	 a	 stress-induced	 senescence	
pathway	in	MCF-7	breast	cancer	cells	(Abrahams	et	al.,	2008).	Furthermore,	shRNA	
knock-down	 of	 TBX2	 or	 TBX3	 in	 two	 vertical	 growth	 phase	 melanoma	 cell	 lines	
showed	that	TBX2	plays	a	predominantly	pro-proliferative	and	transformative	role	in	
a	mechanism	 involving	 p21	 repression	 –	 a	 finding	 that	 was	 reproducible	 in	MCF7	
breast	cancer	cells	(Peres	et	al.,	2010).	Despite	its	clear	influence	on	the	p14ARF–p53–
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p21	 pathway,	 TBX2	 is	 also	 able	 to	 promote	 anchorage	 independent	 growth	 and	




In	 the	 context	 of	 cervical	 cancer,	 TBX2	 protein	was	 found	 to	 be	 overexpressed	 in	
squamous	 cell	 carcinomas	 relative	 to	 adjacent	 normal	 tissues,	 and	 its	 expression	
correlated	with	HPV16	E7	protein	presence	and	lymph	node	metastasis,	but	not	with	
patient	age,	histological	grade	or	invasiveness	(Liu,	Jiang	&	Zhang,	2010b).	TBX2	may	
also	 be	 involved	 in	 the	 regulation	 of	 the	 HPV	 lifecycle;	 TBX2	 (and	 TBX3)	 protein	
interacts	 with	 the	 minor	 L2	 capsid	 protein	 of	 HPV16	 to	 enhance	 TBX2-mediated	
repression	of	the	long	control	region	of	the	integrated	viral	genome,	thus	suggesting	
that	 it	may	also	contribute	 to	 the	 regulation	of	oncovirus-mediated	carcinogenesis	
(Schneider	et	al.,	2013).	
	
Interestingly,	a	protective	 role	 for	TBX2	has	been	suggested	 in	 recent	 literature	on	




hypomethylation	 of	 the	 gene	 had	 significantly	 greater	 5-year	 survival	 rates	 than	
those	exhibiting	hypermethylation	 (Farkas,	Sorbe	&	Nilsson,	2016).	 	Similarly,	TBX2	
methylation	was	also	identified	as	a	strong	predictor	of	bladder	cancer	progression	
in	 two	 independent	 studies,	 with	 low	 methylation	 status	 indicating	 significantly	
greater	10-year	progression-free	 survival	 rates	 (Kandimalla	et	al.,	 2012;	Beukers	et	
al.,	 2015).	 This	 suggests	 that	 TBX2	may	 act	 protectively	 in	 these	 cancers	 and	 that	
silencing	 its	 expression	 is	 required	 for	 them	 to	 progress	 to	 later	 stages.	 A	 full	
characterization	 of	 the	 tumour-suppressor	 activities	 of	 TBX2	 has	 not	 yet	 been	







TBX3	 is	 overexpressed	 in	 a	 number	 of	 primary	 cancer	 tissues,	 including	 head	 and	
neck	squamous	carcinomas,	pancreatic	ductal	carcinomas	and	solid-pseudopapillary	
pancreatic	neoplasms,	gastric	and	colorectal	cancers,	a	diverse	range	of	sarcomas,	a	
subset	 of	 breast	 cancers,	 and	 Wnt-activated	 hepatocellular	 carcinomas	 and	
hepatoblastomas	(Fan	et	al.,	2004;	Renard	et	al.,	2007;	Yarosh	et	al.,	2008;	Cavard	et	
al.,	 2009;	 Burgucu	 et	 al.,	 2012;	 Shan	 et	 al.,	 2015;	Wang	 et	 al.,	 2015;	Miao	 et	 al.,	
2016;	Perkhofer	et	al.,	2016;	Willmer,	2016;	Willmer,	Cooper,	et	al.,	2016).	Elevated	
expression	was	 also	 seen	 in	 plasma	obtained	 from	a	 subset	 of	 ovarian	 and	 breast	
cancer	 patients	 relative	 to	 healthy	 controls	 (Lomnytska	 et	 al.,	 2006).	 TBX3	 has	
multiple	roles	in	cancer	and	has	been	shown	to	influence	cell	proliferation,	migration	





migration	 in	 these	cells	 (Peres	et	al.,	2010).	 Indeed,	TBX2	and	TBX3	appear	 to	play	
opposing	roles	during	different	growth	phases	of	melanoma.	Some	of	TBX3’s	effects	
also	occur	 via	 p21.	When	 stably-transfected	 to	 express	 TBX3,	 the	non-tumorigenic	
radial	 growth	 phase	 cell	 line	 WM1650	 showed	 decreased	 proliferative	 rates,	 an	
alteration	 of	 cell	 cycle	 distribution,	 decreased	 levels	 of	 p21,	 TBX2	 and	 E-cadherin,	
and	 increased	 levels	 of	 p53	 and	 p14
ARF
.	 Transfected	 cells	 also	 exhibited	 increased	
migratory	 ability	 and	 anchorage	 independence	 and	 tumour	 forming	 ability	 in	 vitro	
and	 in	vivo	 (Peres	&	Prince,	2013).	Furthermore,	both	TBX3	isoforms	are	expressed	
in	501	mel	and	YUSIT	melanoma	cell	 lines,	but	not	in	the	melanocyte	lines	melan-a	




TBX3-mediated	 repression	 of	 p21	 did	 result	 in	 increased	 rates	 of	 proliferation.	
	 17	





E-cadherin	 expression	 (Boyd	 et	 al.,	 2013).	 E-cadherin	 is	 also	 directly	 repressed	 by	
TBX3	in	this	context	and	TBX3	depletion	led	to	increased	E-cadherin	expression	and	
decreased	invasiveness	 in	 in	vitro	studies.	Depletion	of	TBX3	also	 led	to	substantial	
increases	 in	TBX2	expression,	 further	 supporting	 the	concept	of	opposing	 roles	 for	
TBX2	 and	 TBX3	 in	 melanoma	 proliferation	 (Rodriguez	 et	 al.,	 2008).	 The	 AKT3	
pathway	is	an	important	regulator	of	melanomagenesis	and	TBX3	has	been	shown	to	
be	 a	 key	 substrate	 of	 this	 pathway	 in	 this	 context;	 TBX3	phosphorylation	 by	AKT3	
increases	its	stability,	enhances	nuclear	localization	and	the	repression	of	E-cadherin	
expression	both	in	vitro	and	in	vivo,	leading	to	enhanced	cell	migration	and	invasion	
of	 melanoma	 cells	 (Peres,	 Mowla	 &	 Prince,	 2014).	 Similar	 effects	 of	 TBX3	 in	
proliferation	and	migration	were	also	observed	in	MCF-7	breast	cancer	cells	as	well	
as	 in	 breast	 epithelial	 cells	 (Peres	 et	 al.,	 2010;	 Li,	 Weinberg,	 et	 al.,	 2013).		
Furthermore,	 TBX3	may	 reinforce	 its	 own	AKT-pathway	 driven	 phosphorylation	 by	
repressing	expression	of	tumour	suppressor	phosphatase	and	tensin	homolog	(PTEN)	
(Burgucu	et	al.,	2012).	PTEN	antagonizes	phosphoinositide	3-kinase	(PI3K)	signaling	
to	 inactivate	 it	 and	 the	 downstream	 AKT	 pathway	 (Leevers,	 Vanhaesebroeck	 &	
Waterfield,	 1999).	 Inactivation	 of	 PTEN	 results	 in	 subsequent	 activation	 of	 the	




TBX3	 also	 acts	 as	 a	 tumour	 suppressor	 in	 some	 instances.	 Like	 TBX2,	 TBX3	 also	
interacts	 with	 the	 HPV16	 L2	 capsid	 protein	 to	 enhance	 viral	 gene	 repression	
(Schneider	et	al.,	2013).	However,	unlike	TBX2,	TBX3	expression	 in	cervical	cancers	
appears	 to	 be	 onco-protective.	 TBX3	 mRNA	 was	 downregulated	 in	 node-positive	







growth	 in	 these	 cells	 (Willmer,	 Cooper,	 et	 al.,	 2016).	 Finally,	 TBX3	 is	 also	 highly	
methylated	 in	 glioblastoma,	 gastric	 and	 bladder	 cancers.	 Increased	 methylation	
negatively	 correlated	 with	 survival	 in	 glioblastomas	 and	 in	 bladder	 cancers	 was	
associated	 with	 a	 greater	 likelihood	 to	 progress	 to	 muscle-invasive	 tumours	 and	




exhibit	 reduced	 or	 abrogated	 protein	 function	 (Fischer	 &	 Pflugfelder,	 2015).	
Collectively,	 it	 is	 clear	 that	 a	 tumour	 suppressor	 role	 is	 possible	 for	 TBX3	 in	 some	









TBX1	 and	 TBX4	 have	 been	 implicated	 as	 potential	 tumour	 suppressors.	 TBX1	
expression	 is	 reduced	 in	 mouse	 skin	 tumours	 and	 when	 overexpressed	 in	 mouse	
spindle	 carcinoma	 cells	 it	 conveys	 oncoprotective	 effects	 (Trempus	 et	 al.,	 2011).	
TBX4	has	been	suggested	as	a	potential	biomarker	for	pancreatic	ductal	carcinomas	
where	it	predicts	good	prognostic	outcomes	(Qi	et	al.,	2008;	Zong,	Meng	&	Li,	2011).	
TBX15	and	T-bet	 (TBX21),	 on	 the	other	hand,	 appear	 to	have	oncogenic	potential.	








or	 tumour	 suppressors	 depending	 on	 the	 cellular	 context.	 Brachyury	 expression	 is	
upregulated	in	a	number	of	epithelial-derived	cancers	relative	to	normal	tissues	and	
its	 expression	 appears	 to	 promote	 epithelial-to-mesenchymal	 transition-related	
cancer	 phenotypes	 (Palena	 et	 al.,	 2007;	 Imajyo	 et	 al.,	 2012;	 Sarkar	 et	 al.,	 2012;	
Shimoda	et	al.,	2012).	Furthermore,	Brachyury	expression	was	correlated	to	tumour	
stage	in	human	lung	tumour	tissues,	indicating	a	biological	role	in	cancer	progression	
(Fernando	et	al.,	 2010).	 Brachyury	 also	promoted	 resistance	 to	 chemotherapy	and	
radiotherapy	 in	 lung	carcinoma	models	 (Huang	et	al.,	2013).	 In	contrast,	Brachyury	
has	 also	 shown	 potential	 as	 a	 tumour	 suppressor	 in	 primary	 non-small	 lung	 cell	
carcinomas;	 preliminary	 research	 showed	 that	 Brachyury	 mRNA	 expression	 levels	
were	decreased	relative	to	normal	tissue	levels	(Park	et	al.,	2008).	TBX5	also	seems	
to	play	contradictory	 roles	 in	different	cancer	contexts.	Ectopic	expression	of	TBX5	
inhibits	 colony	 formation	and	 increases	 the	 rate	of	apoptosis	 in	osteosarcoma	and	
lung	 carcinoma	 cell	 lines	 (He	 et	 al.,	 2002).	 Additionally,	 TBX5	 is	 silenced	 or	
downregulated	 in	 a	number	of	 colon	 cancer	 cell	 lines	 relative	 to	normal	 cells,	 and	
TBX5	methylation	was	 detected	 in	 68%	 of	 primary	 colon	 tumours	 tested	 and	was	
associated	with	decreased	overall	survival	(Yu	et	al.,	2010).	However,	other	research	
has	 shown	 that	 TBX5	 is	 essential	 in	 the	 transformation	 and	 survival	 of	 β-catenin	
driven	cancer	cell	lines,	including	a	number	of	colon	cancers	(Rosenbluh	et	al.,	2012).	
	
Finally,	 T-bet	 and	 Eomes	 may	 indirectly	 affect	 cancer	 progression	 by	 influencing	
immune	 responses.	 Colorectal	 cancers	 lacking	 signs	 of	 early	 metastatic	 invasion	
exhibit	 less	 T-bet	 mRNA	 expression	 relative	 to	 tumours	 that	 do	 show	 such	 signs	
(Pagès	et	al.,	2005).	Given	that	T-bet	is	required	for	naive	CD4+	T	cell	differentiation	
into	type	1	helper	T	cells	in	response	to	Interferon	Gamma	(IFN-γ)	stimulation	(Szabo	
et	 al.,	 2003),	 it	 seems	 likely	 that	 T-bet	 may	 be	 a	 marker	 of	 an	 effective	 immune	
response	 targeting	 these	 tumours.	Reduced	Eomes	expression	was	correlated	with	
lymph	node	metastasis	in	a	study	on	colorectal	cancer	tissues	and	Eomes	expression	
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in	 CD8+	 T	 cells	 regulates	 IFN-γ	 expression,	 perforin	 levels	 and	 cytolitic	 activity	 of	
CD8+	 T	 cells.	 Low-expression	 of	 Eomes	 may	 therefore	 result	 in	 a	 poor	 immune	
response	to	colorectal,	and	possibly	other,	cancers	(Atreya	et	al.,	2007).	Eomes	and	
T-bet	also	collectively	decide	CD8+	T	cell	fate	and	promote	and	maintain	effector	and	







Semen	 can	 be	 separated	 into	 two	 distinct	 components;	 sperm,	 the	 male	 gamete	
responsible	 for	 transmission	 of	 genetic	material	 from	 the	 paternal	 parent	 into	 an	
ovum,	and	seminal	fluid	(SF,	also	called	seminal	plasma),	the	liquid	within	which	the	
sperm	are	deposited	into	the	female	reproductive	tract.	Once	thought	to	simply	act	
as	 an	 ideal	 environment	 for	 sperm	 survival	 during	 transport	 and	 fertilization,	
accumulating	evidence	 indicates	 that	SF	also	contributes	 to	a	successful	pregnancy	
by	immunomodulation	of	the	female	reproductive	tract	tissues	and	immune	system	
in	 a	 range	 of	mammals,	 including	 humans	 (Schjenken	&	 Robertson,	 2014).	 At	 the	
molecular	 level,	 the	 effects	 of	 SF	 on	 mammalian	 pregnancy	 appear	 to	 be	 largely	
related	 to	 immunomodulation	 (Bromfield,	 2014;	 Robertson	 &	 Sharkey,	 2016).	





Several	 glands	 in	 the	 male	 reproductive	 tract	 contribute	 specific	 factors	 to	 the	
production	 of	 SF	 (see	 Figure	 1.3);	 the	 resultant	 fluid	 is	 a	 complex	 mixture	 of	
biomolecules,	 from	simple	 sugars	 to	 complex	macromolecules	 (see	Table	1-1).	The	
unique	peptides	and	proteins	alone,	as	identified	my	mass	spectrometry,	number	in	
the	hundreds	 to	 thousands	 (Fung	et	al.,	 2004;	Pilch	&	Mann,	2006;	Batruch	et	al.,	
2011).	Furthermore,	the	concentrations	of	various	constituents	varies	from	ejaculate	
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to	ejaculate,	both	 intra-	and	 inter-personally	 (see	Table	1-1)	 (Sharkey	et	al.,	2016).	
While	many	constituents	certainly	play	a	role	in	the	maintenance	and	protection	of	
sperm,	 some	 also	 elicit	 signaling	 responses	 in	 the	 female	 reproductive	 tracts	 of	
various	 mammals,	 including	 humans	 (Schjenken	 &	 Robertson,	 2014;	 Robertson	 &	
Sharkey,	2016).		
	
Finally,	 SF	 also	 contains	 numerous	 types	 of	 extracellular	 vesicles	 (Machtinger,	
Laurent	 &	 Baccarelli,	 2016).	While	 specific	 roles	 for	 these	 vesicles	 have	 not	 been	
















The	 degree	 to	 which	 SF	 contributes	 to	 a	 successful	 human	 pregnancy	 remains	
somewhat	 controversial	 in	 the	 literature	 (Bedford,	 2015;	 Robertson	 &	 Sharkey,	
2016).	 Given	 the	 countless	 successful	 births	 that	 have	 occurred	 via	 assisted	
reproductive	 therapies	 (ARTs)	 in	 the	 absence	 of	 SF,	 it	 is	 clear	 that	 it	 is	 not	 an	
essential	 factor	 in	human	childbirth.	Furthermore,	 the	difficulties	of	studying	these	










The	 findings	 of	 studies	 attempting	 to	 describe	 the	 effects	 of	 SF	 on	 successful	
pregnancies	 are	 conflicting.	One	 study	 found	 that	women	partaking	 in	 coitus	with	
their	partners	during	peri-transfer	periods	of	in	vitro	fertilization	(IVF)	cycles	did	not	








and	 to	 their	 relationship	 with	 the	 woman.	 Women	 treated	 with	 IVF	 or	
intracytoplasmic	sperm	injection	using	their	partner’s	sperm	and	SF	exhibit	a	third	of	
the	 risk	 of	 preeclampsia	 (a	 syndrome	 thought	 to	 be	 caused	 by	 failed	 induction	 of	
maternal	 immunotolerance	 towards	 the	 semi-allogenic	 fetus)	 compared	 to	 those	
undergoing	 the	 same	 procedures	 with	 sperm	 that	 they	 had	 not	 previously	 been	
exposed	 to	 (Wang	 et	 al.,	 2002).	 Similarly,	 women	 undergoing	 intrauterine	
insemination	 with	 washed	 sperm	 from	 a	 donor	 were	 more	 likely	 to	 develop	
preeclampsia	 than	 those	 receiving	 sperm	 from	 their	 partner.	 In	 this	 instance	
however,	the	antigenic	factor	appears	to	be	associated	with	the	sperm,	and	not	the	
fluid	(Smith	et	al.,	1997).	Yet	other	studies	found	that	cumulatively	increased	vaginal	
exposure	 to	 paternal	 semen	 or	 duration	 of	 relationship	 prior	 to	 conception	 is	
significantly	 inversely	correlated	with	preeclampsia	risk	 (Kho	et	al.,	2009;	Saftlas	et	
al.,	2014).	Yet	another	study	found	that	intrauterine	insemination	using	donor	sperm	
was	 found	 to	 increase	 the	 incidence	 of	 preeclampsia	 and	multiple	 cycles	with	 the	
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same	donor	sperm	appear	to	convey	a	weakly	protective	effect	(Kyrou	et	al.,	2010).	






on	 babies	 mediated	 by	 SF	 exposure.	 Infants	 conceived	 via	 ART	 have	 ~2-fold	
increased	 risk	of	perinatal	mortality,	 low	birth-	 and	preterm	birth	weight,	 are	50%	
more	 likely	 to	 be	 small	 for	 their	 gestational	 age	 and	 a	 30-35%	 increase	 in	 birth	
defects	is	observed	relative	to	naturally	conceived	infants	(Bower	&	Hansen,	2005).	
Additionally,	a	subset	of	babies	born	from	women	who	have	shorter	pre-conception	




data	 are	 only	 extrapolative	 at	 this	 point	 given	 the	 relatively	 young	 age	 of	 the	
technology	 (Hart	 &	 Norman,	 2013).	 	 While	 it	 would	 be	 impossible	 to	 determine	





Both	 animal	 and	 human	 studies	 have	 shown	 that	 SF	 exposure	 results	 in	
immunological	changes	 in	the	female	reproductive	tract.	 In	mice,	a	soluble	form	of	
CD38	 released	 from	 the	 seminal	 vesicles	 induces	 the	differentiation	of	 tolerogenic	
dendritic	cells	and	CD4+	Fox3p+	regulatory	T	cells,	thus	protecting	the	semiallogenic	
fetus	 from	 resorption	 (Kim	 et	 al.,	 2015).	 In	 an	 in	 vitro	model,	 it	 was	 shown	 that	
human	T	cells	also	increase	mRNA	expression	levels	of	CD25	and	Fox3p	in	response	




immune	 induction	 and	 cell-mediated	 immunity	 in	 the	 female	 reproductive	 tract	
(Pudney,	2005).	The	overall	repertoire	of	leukocytes	in	the	cervix	is	altered	through	
intercourse.	CD4+	T	lymphocytes	are	found	in	higher	concentrations	in	women	who	
have	 recently	 experienced	 intercourse,	whereas	 those	who	 have	 not	 exhibit	more	
macrophages	 (Prakash	 et	 al.,	 2003).	 Another	 study	 found	 increased	 CD45+	 cells	
(mostly	 comprising	 CD14+	 macrophages	 and	 CD1a+	 dendritic	 cells)	 following	
intercourse	 in	cervical	biopsies	compared	to	biopsies	 from	the	same	women	taken	
prior	to	intercourse	(Sharkey	et	al.,	2012).	It	is	possible	that	the	immunomodulatory	
roles	of	 SF	vary	according	 to	 the	 recipient’s	ovulatory	 cycle;	work	by	Kimura	et	al.	
(2009)	showed	that	CD16+CD56+	bright	cells	were	more	common	in	cervical	biopsies	
of	 pre-ovulatory	 women	 who	 had	 recently	 had	 intercourse	 compared	 to	 post-





Inflammation	 is	 considered	a	 tumour-enabling	characteristic	of	 cancer	 (Hanahan	&	
Weinberg,	 2011).	 SF	 contains	 many	 pro-inflammatory	 cytokines	 and	 is	 able	 to	
further	 induce	expression	of	 immune-related	molecules	 in	the	female	reproductive	
tract.	 It	 is	 able	 to	 stimulate	 cytokine	production	 in	 cervical	 cells;	 SF	was	 shown	 to	
induce	mRNA	expression	of	over	300	genes	in	primary	ectocervical	cells	as	well	as	in	




End1	 was	 shown	 to	 be	 less	 responsive	 in	 this	 respect.	 Given	 the	 biological	
orientation	of	the	endo-	and	ectocervix,	it	is	tempting	to	speculate	that	this	may	be	
physiologically	 significant,	 as	 ectocervical	 cells	 undergo	 greater	 and	 primary	
exposure	 to	 SF.	 While	 it	 was	 clear	 that	 SF	 could	 induce	 inflammatory	 cytokine	
production,	 significant	 inter-donor	 variation	 in	 cytokine-inducing	 ability	 was	
reported	 (Sharkey	 et	 al.,	 2007).	 This	 inflammatory	 response	 is	 also	 observed	 in	
cancerous	cervical	tissues.	IL-1α	mRNA	is	upregulated	in	both	cervical	squamous	cell	
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carcinoma	 and	 adenocarcinoma	 tissue	 explants	 relative	 to	 normal	 cervical	 tissue,	
and	SF	can	further	induce	its	expression	in	both	cancerous	and	normal	tissues	as	well	
as	 in	HeLa	cells,	predominantly	via	the	EP2/EGFR/PI3K	signaling	pathway	(Adefuye,	
Sales	 &	 Katz,	 2014).	 SF	 is	 also	 able	 to	 induce	 expression	 of	 the	 angiogenic	 factor	
Vascular	 Endothelial	 Growth	 Factor	 A	 (VEGFA),	 among	 others,	 in	 cervical	 tissues	
(Muller	et	al.,	2006).	Given	the	apparent	role	of	SF	as	an	inflammatory	agent	as	well	
as	an	inducer	of	angiogenesis	(yet	another	hallmark	of	cancer),	it	may	play	a	role	in	
encouraging	 the	 onset	 and/or	 progression	 of	 cancers	 of	 the	 female	 reproductive	
tract	(Wang	et	al.,	2010;	Hanahan	&	Weinberg,	2011;	Sales	&	Katz,	2012).		
	
SF	 induces	 changes	 in	 cervical	 tissues	 via	 a	 number	 of	 pathways.	 Transforming	
growth	 factor-β	 (TGF-β)	 elicits	 changes	 in	 Ect1	 cell	 expression	 of	 several	 pro-
inflammatory	 cytokine	 and	 chemokine	 genes,	 replicating	 principal	 aspects	 of	 the	
Ect1	response	to	SF	and	induced	a	similar	IL-6	and	CSF2	response	in	primary	cervical	
epithelial	 cells.	 TGF-β-neutralizing	 antibodies,	 receptor	 antagonists,	 and	 signaling	
inhibitors	ablated	seminal	plasma	induction	of	CSF2	and	IL-6,	but	did	not	alter	IL-8,	
CCL2,	 CCL20,	 or	 IL-1α	 production	 (Sharkey,	Macpherson,	et	 al.,	 2012).	 Indeed,	 the	
EP2/EGFR/PI3K	signaling	pathway	 is	 the	predominant	 regulator	of	 IL-1α	expression	
in	both	normal	and	cancerous	cervical	tissues	(Adefuye,	Sales	&	Katz,	2014).	IL-8	and	
growth-regulated	 oncogene	 α	 expression	 are	 increased	 via	 transactivation	 of	 the	
epidermal	 growth	 factor	 receptor	 (EGFR),	 activation	 the	 Extracellular	 Signal-




major	 factor	 influencing	 PTGS2	 expression	 (Joseph	 et	 al.,	 2013).	 	 SF	 also	 exerts	
PTGS2	and	VEGF	inducing	activity	 in	HeLa	cells	via	the	prostaglandin	EP-4	receptor,	
EGFR	and	ERK1/2	signaling	pathways,	initiating	or	exacerbating	a	potentially	already-
present	positive	 feedback	 loop	 in	 these	 cells	 (Muller	et	al.,	 2006).	Upregulation	of	
PTGS2	by	SF	is	also	observed	in	vaginal	and	cervicovaginal	explants	and	SF	treatment	
synergistically	 potentiates	 other	 stimulants	 in	 doing	 the	 same.	 Taken	 together,	 SF	
clearly	 induces	 multiple	 cellular	 changes	 in	 a	 variety	 of	 tissues	 of	 the	 female	
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treated	 with	 intraperitoneal	 SF	 injection	 showed	 increased	 inflammatory	 enzyme,	
cytokine	 and	 VEGFA	 expression,	 with	 treated	 mice	 developing	 larger,	 more	
vascularised	tumours	more	rapidly	than	control	mice	(Sutherland	et	al.,	2012).	This	
increased	 rate	 of	 xenograft	 HeLa	 tumour	 formation	 has	 also	 been	 observed	
elsewhere,	 where	 SF	 was	 injected	 together	 with	 tumour	 cells,	 rather	 than	 being	
intraperitoneally	administered	post-HeLa	cell	injection	(Liu	et	al.,	2011).	Physiological	
changes	 are	 not	 limited	 to	 cervical	 tissues;	 treatment	 of	 primary	 endometrial	
epithelial	 and	 stromal	 cell	 culture	 models	 with	 SF	 induces	 transcription	 of	 genes	
associated	 with	 migration,	 proliferation,	 viability	 and	 inhibition	 of	 cell	 death.	










Cervical	 cancer	 is	 primarily	 caused	 by	 HPV	 infection;	 however,	 other	 factors	 also	
contribute	 to	 its	 development.	 Consequently,	 regular	 screening	 and	 early	
intervention	significantly	reduces	morbidity	and	mortality	(American	Cancer	Society,	
2014).	 Furthermore,	 vaccines	against	high-risk	HPVs	have	 recently	been	developed	
and	have	markedly	reduced	the	incidence	of	HPV	infection	in	vaccinated	populations	
(Garland	 et	 al.,	 2015;	 Herrero,	 González	 &	 Markowitz,	 2015;	 Joura	 et	 al.,	 2015).	
Despite	 these	 great	 strides	 in	 prevention,	 however,	 cervical	 cancer	 remains	 a	
pressing	 issue.	 As	 previously	mentioned,	 the	 burden	 of	 disease	 disproportionately	
falls	on	 the	developing	world,	where	access	 to	 screening	and	vaccinations	 remains	
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limited	 (see	 section	 1.1.1).	 These	 populations	 will	 thus	 continue	 to	 exhibit	
disproportionate	 morbidity	 rates.	 Beyond	 the	 necessary	 HPV	 infection	 and	 viral	






Liu,	 Jiang	 &	 Zhang,	 2010b).	 Furthermore,	 both	 proteins	 repress	 viral	 gene	
transcription	at	the	LCR	of	a	number	of	HPV	subtypes,	and	interaction	with	HPV16	L2	
capsid	protein	augments	 their	 repressive	effects	 (Schneider	et	al.,	 2013).	While	no	
mechanisms	 have	 been	 presented,	 it	 is	 clear	 that	 these	 proteins	 are	 in	 some	way	
involved	in	the	HPV	lifecycle	and	therefore	possibly	also	cervical	oncogenesis.		
	






















1. To	determine	whether	TBX3	protein	expression	 is	altered	 in	 cervical	 cancer	
tissues	compared	to	normal	cervical	tissues	in	vivo.	
2. To	 determine	 whether	 SF	 treatment	 influenced	 TBX2	 or	 TBX3	 gene	
expression	in	cervical	cancer	cell	culture	models.	









Standard	 laboratory	 reagents	 were	 purchased	 from	 Sigma-Aldrich	 unless	 stated	
otherwise.	HeLa	(ATCC®	CCL-2™),	CaSki	(ATCC®	CRL-1550™)	and	C-33	A	(ATCC®	HTB-
31™)	cells	were	obtained	from	laboratory	stocks	and	were	originally	purchased	from	
the	 American	 Type	 Culture	 Collection.	 Formalin-fixed,	 paraffin-embedded	 (FFPE)	
histological	 slides	 with	 cervical	 adenocarcinoma,	 squamous	 cell	 carcinoma	 and	
normal	tissue	biopsy	samples	mounted	on	them	were	obtained	from	the	Division	of	
Anatomical	 Pathology,	 Faculty	 of	 Health	 Sciences,	 University	 of	 Cape	 Town	 (UCT),	
Cape	 Town,	 South	 Africa.	 Semen	 was	 obtained	 from	 healthy	 male	 volunteers	
attending	 the	 Andrology	 Laboratory	 of	 the	 Reproductive	Medicine	 unit	 at	 Groote	
Schuur	Hospital,	Cape	Town,	South	Africa.	 Informed	consent	was	obtained	from	all	













washed	 twice	 with	 phosphate-buffered	 saline	 (PBS,	 appendix	 II),	 followed	 by	
addition	 of	 4	mL	 Trypsin/EDTA	 (21	 μM	 /	 684	 μM	 in	 PBS).	 After	 a	 brief	 incubation	
period	 at	 37°C,	 cells	were	 examined	by	 positive	 phase	 contrast	microscopy	with	 a	
TMS	inverted	microscope	(Nikon	Instruments,	Netherlands)	to	assess	the	degree	of	
detachment.	 Once	 sufficiently	 detached,	 6	 mL	 complete	 medium	 was	 added	 to	
inactivate	 the	 Trypsin/EDTA	 and	 a	 portion	 of	 the	 suspension	 (3	mL	 for	 CaSki	 and	
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HeLa	 cells,	 4	 mL	 for	 C-33	 A)	 was	 returned	 for	 culturing.	 The	 remaining	 cell	
suspensions	were	 used	 in	 experiments	 or	 discarded.	 Cells	were	 incubated	 in	 37°C	










mounting	 fluid	 (see	 appendix	 II).	 Slides	 were	 examined	 using	 an	 Axioskop	 2	MOT	
fluorescence	microscope	(Zeiss	GmbH)	utilizing	an	HBO	100	mercury	short	arc	lamp	








tissues	 were	 embedded.	 They	were	 then	 deparaffinised	 and	 rehydrated	 by	 two	 5	
minute	 washes	 in	 xylene	 (Merck)	 followed	 by	 5	 minute	 washes	 in	 a	 decreasing	
alcohol	gradient	(100%,	100%,	95%,	70%,	50%,	Merck)	and	rinsed	in	deionized	water	
(dH2O).	 Antigen	 retrieval	 was	 performed	 by	 immersing	 slides	 in	 0.01	 M	 sodium	
citrate	 (pH	6)	 inside	a	pressure	cooker	 (Russell	Hobbs,	South	Africa)	 for	2	minutes.	
Thereafter	 the	 pressure	was	 released	 and	 the	 cooker	was	 placed	 in	 cold	water	 to	
cool	to	room	temperature.	Slides	were	washed	with	dH2O	before	being	incubated	in	
3%	 hydrogen	 peroxide,	 diluted	 in	 methanol,	 for	 30	minutes	 on	 a	 shaker	 at	 room	
temperature	 (RT)	 to	 eliminate	 endogenous	 peroxidase	 activity.	 They	 were	 then	
rinsed	 in	dH2O	and	washed	for	5	minutes	 in	tris-buffered	saline	(TBS,	see	appendix	
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II).	 Slides	 were	 then	 blocked	 with	 5%	 normal	 goat	 serum	 (Dako,	 ref	 no:	 X0907)	
diluted	 in	 TBS	 for	 30	 minutes	 in	 a	 humidifying	 chamber.	 Excess	 goat	 serum	 was	
drained	 and	 slides	 were	 incubated	 with	 primary	 antibody	 solution	 (anti-TBX3	
polyclonal	 antibody	 (Abcam,	 AB99302)	 diluted	 1:20	 in	 TBS),	 or	 5%	 normal	 goat	
serum	 in	 the	 case	 of	 secondary	 only	 controls,	 in	 a	 humidifying	 chamber	 at	 4°C	
overnight.	Slides	were	then	washed	twice	for	5	minutes	in	TBS,	after	which	1-2	drops	
of	secondary	antibody	(anti-rabbit	Envision+	System	HRP-labeled	polymer	(Dako,	ref	
no:	 K4002))	 was	 applied	 to	 each	 slide	 before	 being	 returned	 to	 the	 humidifying	
chamber	for	30	minutes	at	RT.	Slides	were	again	washed	twice	in	TBS	for	5	minutes	
and	1-2	drops	of	chromogenic	 substrate	DAB	 (3,3'-diaminobenzidine,	Dako,	 ref	no:	
K3467)	was	added	to	each	slide	for	10	minutes,	after	which	they	were	rinsed	in	dH2O	
and	counterstained	with	Mayer’s	Hematoxylin	and		Scott’s	tap	water	substitute	(see	
appendix	 II)	 for	1	minute	each.	Sections	were	then	dehydrated	by	 immersion	 in	an	
increasing	alcohol	gradient	 followed	by	xylene	 (the	reverse	of	 the	above,	1	minute	







et	 al.,	 2012)	 and	 colour-corrected	 by	 background	 subtraction.	 	 Thereafter	 stromal	
sections	were	digitally	 removed	 (if	possible),	 to	 leave	only	normal	epithelial	 cell	or	
cancerous	tissue	area.	Image	de-convolution	(H-DAB)	and	automatic	thresholding	of	













following	 72	 hours	 of	 sexual	 abstinence.	 	 A	 trained	 technician	 confirmed	 that	 all	
semen	was	 within	 reference	 values	 for	 normal	 semen	 as	 stipulated	 by	 the	World	
Health	Organisation	(Cooper	et	al.,	2010).	Semen	was	processed	within	30	minutes	
of	collection.	Collected	semen	was	separated	into	sperm	and	SF	by	centrifugation	at	
15	 000	 x	 g	 for	 20	 minutes	 at	 4°C.	 The	 supernatant	 was	 transferred	 to	 sterile	






1:50.	 This	 dilution	 was	 chosen	 as	 it	 does	 not	 influence	 the	 viability	 of	 HeLa	 cells	
(Jeremias	et	al.,	1997),	whereas	higher	concentrations	have	been	shown	to	reduce	
the	viability	of	a	number	of	cell	lines	(Nocera	&	Chu,	1993;	Kim	et	al.,	2010;	Chen	et	






experiments	 (section	 2.6)	 HeLa	 (5	 x	 10
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each	 assembly	 and	 centrifuged	 as	 above.	 This	 process	 was	 repeated	 with	 500	 µL	
Wash	 Buffer	 II	 (appendix	 II)	 and	 again	 with	 200	 µL	Wash	 Buffer	 II,	 with	 the	 final	
centrifugation	 at	 13	 000	 x	 g	 for	 2	minutes.	 Finally,	 samples	 were	 eluted	 in	 40	 µL	















ImProm-II™	 Reverse	 Transcription	 Systems	 (Promega)	 were	 used	 to	 reverse-
transcribe	 isolated	RNA	to	produce	complementary	DNA	(cDNA).	Equal	amounts	of	
RNA	per	 sample	were	 reverse	 transcribed	within	each	experiment.	Reactions	were	
performed	according	to	the	manufacturer’s	 instructions.	Briefly:	up	to	1	µg	of	RNA	
was	 combined	with	 0.5	 g	 oligo	 (dT)	 primer	 and	nuclease-free	water	was	 added	 to	
make	a	final	volume	of	5	µL	per	reaction.	Samples	were	then	incubated	at	70°C	for	5	
minutes	 to	 denature	 the	 RNA,	 followed	 by	 incubation	 on	 ice.	 Thereafter	 15	 µL	 of	
reverse	 transcription	mix	 (1X	 ImProm-	 II
TM
	 Reaction	 buffer,	 3	mM	MgCl2,	 0.5	mM	




control	 was	 also	 made	 for	 each	 sample,	 wherein	 the	 reverse	 transcriptase	 and	
RNasin®	were	substituted	with	nuclease-free	water.	Reactions	were	then	incubated	
at	25°C	for	5	minutes	(primer	annealing),	then	42°C	for	1	hour	(reverse	transcription)	
and	 finally	70°C	 for	15	minutes	 (inactivation	of	 reverse	transcriptase).	The	samples	





Real	 time	quantitative	PCR	 (qPCR)	 reactions	were	performed	using	a	StepOne	Plus	
PCR	 System	 (Applied	 Biosystems,	 UK).	 Reactions	 were	 performed	 in	 MicroAmp	
optical	96-well	plates	or	8-well	strips	(Applied	Biosystems).	Per	well,	2	µL	of	diluted	
cDNA	 was	 combined	 with	 8	 µL	 of	 qPCR	 MasterMix	 (FG-Power	 SYBR®	 Green	 PCR	
Master	 Mix	 (Applied	 Biosystems),	 10	 µM	 forward	 primer,	 10	 µM	 reverse	 primer)	
	 36	
containing	 the	 appropriate	 primers	 for	 each	 gene	 being	 investigated.	 Unless	
otherwise	stated,	all	cDNA	samples	were	diluted	1/5	prior	to	amplification.	Samples	
were	measured	 in	 triplicate	 in	each	experiment.	Matching	no-reverse-transcription	
controls	 (also	 diluted	 1/5)	 were	 included	 for	 each	 sample-target	 pair	 and	 no-
template	controls	(where	cDNA	is	replaced	with	nuclease-free	water)	were	included	
for	each	target	gene	in	all	experiments.	Continuous	melt	curves	were	included	in	all	
experiments	 to	 confirm	 the	 production	 of	 single	 amplicon	 products	 and	 to	 assess	

















laboratory,	 Department	 of	Molecular	 Cell	 Biology,	 UCT.	 TBX2	 (QT00091266),	 TBX3	
(QT00022484),	 GUSB	 (QT00046046),	 p21	 (QT00062090)	 and	 PTEN	 (QT01676969)	




















4	 Elongation	 60	 1	min	
5	 Final	denaturation	 95	 15	sec	 1	











which	was	 subsequently	 imported	 into	qBase+	version	2.6.1	 (Biogazelle).	Replicate	
measurements	that	differed	by	more	than	0.5	quantification	cycles	(Cq,	also	known	
as	 threshold	 cycles,	 Ct)	 were	 excluded	 from	 analysis.	 Negative	 control	 thresholds	
(difference	 between	 control	 Cq	 values	 and	 the	 highest	 Cq	measured	 for	 a	 specific	
gene	 in	 a	 specific	 run)	 were	 set	 at	 <5	 Cq.	 Failing	 reactions	 were	 excluded	 from	
further	 analysis.	 Relative	 quantitation	was	 performed	with	 efficiency	 correction	 as	
described	 by	Hellemans	et	 al.	 (2007).	 Briefly:	 primer	 efficiencies	were	 determined	
for	all	primers	by	creating	a	standard	curve	dilution	series	of	a	sample,	from	which	
the	 slope	 and	 its	 standard	 error	 was	 calculated	 by	 linear	 regression.	 Normalised	
relative	 quantities	 (NRQ)	 of	 each	 gene	 in	 a	 given	 sample	 were	 determined	 as	
described	 in	 equation	 2.	 All	 expression	 was	 normalized	 to	 two	 reference	 genes,	
GUSB	 and	 HSPC90AB1	 (see	 section	 3.2).	 qBase+	 was	 also	 used	 to	 determine	
reference	gene	expression	 stability	 via	GeNorm	 (see	 section	3.2)(Vandesompele	et	
al.,	 2002).	 Target-specific	 amplification	 efficiences	 for	 both	 reference	 and	 target	
genes	 were	 applied	 to	 all	 calculations.	 Reference	 genes	 were	 considered	 stable	
within	an	experiment	if	GeNorm	analysis	returned	an	M-value	<	0.5	and	a	coefficient	
of	variation	<	0.2	(Hellemans	et	al.,	2007).	Where	appropriate,	 inter-run	calibration	











Δ!" =  difference of Cq values of a sample of interest and a scaling sample 
!"# =  gene of interest	
!"# =  reference gene	













HPRT1	 TGAGGATTTGGAAAGGGTGTT	 57.39	 CAGAGGGCTACAATGTGATGG	 58.43	 111	
EEF1A1	 TGCGGTGGGTGTCATCAAA	 59.85	 AAGAGTGGGGTGGCAGGTAT	 61.12	 123	
HSPC90	
AB1	 ATGGAAGAGAGCAAGGCAAA	 57.41	 AATGCAGCAAGGTGAAGACA	 58.01	 117	
GUSB	 Proprietary	 55	 Proprietary	 55	 96	
P21 Proprietary	 55	 Proprietary	 55	 79	
PTEN	 Proprietary	 55	 Proprietary	 55	 111	
TBX2	 Proprietary	 55	 Proprietary	 55	 62	
TBX3	 Proprietary	 55	 Proprietary	 55	 119	
 SDS	Poly	acrylamide	gel	electrophoresis	and	western	blotting	2.7.
Cells	 cultured	 as	 per	 section	 2.5	 were	 placed	 on	 ice	 and	 washed	 twice	 with	 PBS.	
Thereafter	70	µL	 lysis	buffer	 (2	 x	Boiling	Blue,	 see	appendix	 II)	was	added	 to	each	
well	 and	 cells	 were	 lysed	 by	 scraping	 with	 the	 back	 of	 a	 yellow	 pipette	 tip.	 The	
resultant	mixtures	were	transferred	to	sterile	Eppendorf	 tubes	and	heat-treated	to	
denature	 proteins	 at	 95°C	 for	 7	 minutes	 and	 immediately	 returned	 to	 ice.	 Tubes	
were	 inverted	 several	 times	 and	 briefly	 centrifuged.	 Thereafter,	 20	 µL	 of	 each	
sample	 was	 inserted	 into	 wells	 of	 polyacrylamide	 gels	 (4%	 stacking,	 8%	 running)	
containing	sodium	dodecyl	sulfate	(SDS-PAGE,	see	appendix	II)	immersed	in	running	
buffer	(appendix	 II)	and	electrophoresed	at	100	Volts	until	adequate	separation,	as	
judged	by	migration	of	 the	molecular	weight	 ladder	 (PageRuler	 Prestained	Protein	
Ladder,	Thermo	Fisher	Scientific),	was	achieved.	Thereafter,	gels	were	removed	from	
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the	 apparatus,	 the	 stacking	 gel	 section	 was	 excised	 and	 the	 running	 section	 was	








the	 appropriate	 peroxide-conjugated	 secondary	 antibody	 for	 1	 hour	 at	 RT.	
Thereafter	they	were	washed	again	with	PBS/T	and	protein	bands	were	visualised	by	
enhanced	chemiluminescence	(SuperSignal®	West	Pico	Chemiluminescent	Substrate	




Primary	 antibodies	 used	 in	 this	 study	 were	 rabbit	 polyclonal	 anti-TBX3	
(1:1000)(AB99302,	 Abcam),	 goat	 polyclonal	 anti-TBX2	 (1:500)(sc-17880,	 Santa	 Cruz	
Biotechnology),	rabbit	polyclonal	anti-p21	(1:500)(sc-756,	Santa	Cruz	Biotechnology),	
rabbit	 monoclonal	 anti-GAPDH	 (1:20	 000)	 (14C10,	 Cell	 Signaling),	 all	 diluted	 in	
PBS/T+5%	 milk,	 and	 rabbit	 polyclonal	 anti-p38	 	 (1:10	 000)(9219,	 Cell	 Signaling)	






HeLa	 cells	 were	 cultured	 for	 RT-qPCR	 experiments	 as	 described	 in	 section	 2.5.	
However,	 prior	 to	 incubation	with	 SF,	 cells	 were	washed	 twice	with	 PBS,	 starving	
medium	(appendix	II)	was	added	and	cells	were	pre-treated	with	either	Actinomycin	
D	(Act	D,	5	µg/mL),	or	vehicle	(DMSO)	for	1	hour.	SF	(1:50	final	concentration)	was	










in	 complete	medium	 (appendix	 II)	 to	 50%	 confluence.	 Cells	were	 then	 transfected	
with	 50	 nM	 siTBX3	 (SI00083503,	 Qiagen,	 USA)	 or	 siCtrl	 (1027310,	 Qiagen,	 USA)	
siRNA,	as	appropriate,	using	HiPerfect®	transfection	reagent	(Qiagen,	USA)	according	












confirm	cell	 confluence	and	wounds	were	 induced	 into	 the	cell	monolayer	of	each	
well	by	scratching	the	surface	with	a	sterile	pipette	tip.	Each	well	was	then	washed	
twice	with	complete	media	before	addition	of	500µL	complete	media	supplemented	
with	10	µg/mL	mitomycin	C	 to	 inhibit	cellular	proliferation	 throughout	 the	wound-
healing	 assay.	 Treatment-well	 medium	was	 also	 supplemented	with	 SF	 (1:50	 final	
concentration).	 Immediately	 after	 medium	 addition,	 each	 well	 was	 photographed	
using	 a	 digital	 camera	 attached	 to	 an	 Olympus-CKX41	 inverted	 light	 microscope	
(Olympus	Life	Sciences,	South	Africa)	in	three	unique	locations	along	the	wound,	as	
demarcated	by	 lines	drawn	on	the	bottom	of	the	plate	prior	to	cell	seeding.	These	




Once	all	 images	were	taken,	 ImageJ	v.10.2	software	 (Abràmoff,	Magalhães	&	Ram,	
2004)	 was	 used	 to	 determine	 the	 area	 of	 the	 scratch	 in	 each	 image.	 The	 0	 hour	
image	 in	 each	 condition	 served	 as	 the	 reference,	 and	 cell	migration	 distance	was	
determined	by	subtraction	of	the	remaining	area	in	later	images	from	that	of	the	0	










HeLa	 cells	 were	 seeded	 in	 two	 60	 mm	 dishes	 (4	 x	 10
5
	 cells	 /	 dish)	 and	 cultured	





Cells	 were	 lifted	 by	 trypsinisation	 and	 counted	 at	 1,	 3,	 5	 and	 7	 days	 to	 assess	
population	growth.	All	populations	were	resuspended	in	the	same	volume	of	media.	
On	 day	 2	 and	 5	 cells	 that	 were	 not	 being	 counted	 that	 day	 were	 lifted	 and	
transferred	 to	 larger	 culture	 vessels	 to	 avoid	 contact	 inhibition	 of	 proliferation.	







v.6.0c	 (GraphPad	Software,	USA)	was	used	 to	produce	all	 graphs	
and	 to	 conduct	 all	 statistical	 analyses	 presented	 herein,	 unless	 specifically	 stated	
otherwise.	 Statistical	 significance	 was	 defined	 as	 p	 <	 0.05	 in	 all	 analyses.	 The	






While	 the	 expression	 status	 of	 TBX2	 protein	 in	 cervical	 cancers	 relative	 to	 normal	




levels	 of	 TBX3	mRNA	 or	 protein	 expression	 relative	 to	 normal	 cervical	 tissues.	 To	
determine	 whether	 different	 TBX3	 protein	 expression	 levels	 exist	 in	 normal	 and	
cancerous	cervical	tissues,	we	investigated	TBX3	protein	expression	in	FFPE	cervical	
carcinomas	 and	 normal	 tissue	 via	 immunohistochemistry.	 The	 results,	 shown	 in	
Figure	3.1,	 -3.2	and	-3.3,	 indicate	that	TBX3	is	indeed	significantly	overexpressed	in	
both	 cervical	 squamous	 cell	 carcinoma	 (~4,35	 fold,	 p	 <	 0.001;	 n	 =	 3)	 and	
adenocarcinomas	 (~4,45	 fold,	 p	 <	 0.001;	 n	 =	 4)	 relative	 to	 normal	 cervical	 tissues	
from	patients	who	did	not	have	 cervical	 cancer	 (n	 =	3)(Figure	 3.1	 b).	 Additionally,	




the	 squamous	 carcinomas	 tested	 in	 this	 study	 (Figure	 3.2	 a,	 b),	 only	 two	 sections	
contained	 significant	 regions	 of	 normal	 epithelium,	 thus	 precluding	 statistical	
interrogation.	







Formalin-fixed,	 paraffin-embedded	 cervical	 tissues	 were	 probed	 for	 TBX3	 expression	 via	
immunohistochemistry.	 a,	 Staining	 of	 squamous	 carcinoma	 (top),	 adenocarcinoma	 (middle),	 and	
normal	cervix	(bottom).	Staining	with	primary	antibody	directed	against	TBX3	is	displayed	in	a	panel	
on	 the	 left	 (+	 TBX3	 primary	 antibody)	 and	 matching	 secondary	 antibody-only	 control	 slides	 are	
pictured	on	 the	 right	 (-	TBX3	primary	antibody).	b,	Area	of	 staining	of	normal	epithelial	 tissues	and	
cancerous	 tissues	 were	 quantified	 as	 a	 percentage	 of	 total	 staining.	 For	 quantification	 2-3	 images	
were	taken	of	each	section,	depending	on	the	distribution	of	cancerous	tissue.	Resultant	values	were	
averaged	 and	 pooled	 by	 tissue	 type.	 Statistical	 significance	 was	 determined	 by	 ordinary	 one-way	


























(n = 3) (n = 3)(n = 4)
b. 
44	
Figure	3.2:	 TBX3	protein	 is	overexpressed	 in	 cancerous	 tissues	 compared	 to	matched	adjacent	normal	
tissues.		
Formalin-fixed,	 paraffin-embedded	 cervical	 tissues	 were	 immunostained	 with	 antibody	 directed	 against	




distribution	of	 cancerous	 tissue	 throughout	 the	 section.	Resultant	 values	were	averaged	 and	 the	means	


















































In	 order	 to	 test	 this,	 we	 sought	 to	 examine	 the	 relative	 levels	 of	 TBX2	 and	 TBX3	
mRNA	 expression	 in	 SF-treated	 and	 untreated	 cervical	 cancer	 cell	 lines.	 Therefore	
suitable	 reference	 genes	 (also	 called	 house	 keeping	 genes)	 in	 cervical	 cancer	 cells	
had	 to	be	 identified	 in	order	 to	examine	 the	relative	 levels	of	mRNA	expression	of	
these	(and	other)	gene	targets	in	RT-qPCR	experiments.	Multiple	reference	genes	are	
required	 for	 normalization	 of	 gene	 expression	 in	 order	 to	 accurately	 determine	
subtle	differences	in	target	gene	expression	levels	between	samples	(Vandesompele	
et	 al.,	 2002).	 As	 per	 the	MIQE1	guidelines,	 reference	 genes	must	 be	 constitutively	








GUSB,	 HSPC90AB1,	 HPRT1,	 EEF1A1,	 and	 PPIA	 (Steinau,	 Rajeevan	 &	 Unger,	 2006;	






specificity.	 Primers	were	 considered	 to	 be	 target-specific	 if	 the	 BLAST	 search	 only	
returned	 PCR	 products	 of	 a	 single	 size	 that	 aligned	 to	 validated	 sequences	 of	 the	
intended	gene.	Thereafter,	primer	pairs	were	submitted	to	the	RT	Primer	Database	
(rtprimerdb.org)	to	determine	whether	their	binding	regions	contained	known	single	
nucleotide	polymorphisms	 (SNPs)	 that	may	 influence	binding.	 From	 these	analyses	
the	 primers	 for	 HSPC90AB1,	 and	 HPRT1	 were	 confirmed	 as	 suitable	 for	 further	
investigation.	 The	 EEF1A1	 reverse	 primer	 had	 a	 mismatch	 on	 its	 ‘3	 terminal	
nucleotide;	 removal	 thereof	 did	 not	 significantly	 influence	 its	 50%	 melting	
temperature	 (Tm)	 and	 resulted	 in	 a	 perfect	 in	 silico	 alignment	 to	 the	 target	 gene	
sequence.	 The	 modified	 primer	 pair	 was	 therefore	 also	 included	 for	 further	
investigation.	 GUSB	 primers	 were	 purchased	 from	 Qiagen	 and	 have	 proprietary	
sequences,	 thus	 rendering	 in	 silico	 analysis	 impossible.	 However,	 they	 are	
guaranteed	 to	produce	a	 specific	product	under	 the	cycling	conditions	used	 in	 this	
study	 and	 have	 been	 used	 extensively	 in	 our	 laboratory	 in	 the	 past	 and	 therefore	
were	also	included	for	further	analysis.	The	PPIA	primers	were	unable	to	distinguish	





was	 assessed	 using	 the	 GeNorm	 functionality	 in	 qBase+.	 Gene	 expression	 was	
47	
considered	very	 stable	 for	HRPT1,	HSPC90AB1	 and	GUSB	 (GeNorm	M	≤	0.2).	GUSB	
and	HSPC90AB1	were	determined	to	be	the	best	combination	of	genes	with	which	to	
normalize	HeLa	cell	gene	expression	(GeNorm	V	≤	0.15).	While	it	is	recommended	to	
use	 at	 least	 three	 reference	 genes,	 the	 results	 of	 this	 analysis	 indicated	 that	 the	
addition	of	more	reference	genes	did	not	increase	the	strength	of	the	normalisation.	
Reference	 gene	 primer	 amplification	 efficiencies	 were	 determined	 (Table	 3-1);	
efficiencies	 ranging	 between	 85-110%	 were	 considered	 acceptable.	 GUSB	 and	
HSPC90AB1	both	showed	high	efficiencies	and	were	therefore	accepted	as	suitable	
reference	 genes	 for	 use	 in	 this	 study.	 The	 amplification	 efficiencies	 of	 target	 gene	
primers	were	also	determined;	all	primer	pairs	were	confirmed	to	have	acceptable	












EEF1A1	 102,8	 0,051	 0,989	 -3,257 0,116	 9,364	 0,227	
HPRT1	 106,2	 0,083	 0,976	 -3,182 0,178	 19,962	 0,347	
HSPC90AB1	 106,5	 0,055	 0,991	 -3,175 0,116	 14,119	 0,204	
GUSB	 109,7	 0,022	 0,998	 -3,110 0,044	 20,535	 0,082	
Genes	of	
interest	
TBX2	 103,0	 0,022	 0,998	 -3,252 0,050	 27,154	 0,084	
TBX3	 98,7	 0,034	 0,995	 -3,354 0,083	 24,459	 0,141	
p21	 86,7	 0,023	 0,996	 -3,689 0,071	 19,759	 0,134	







HeLa,	C-33	A	and	CaSki	 cells,	were	 treated	with	SF	at	a	 final	 concentration	of	1:50	
and	 incubated	 for	 various	 periods	 spanning	 1-24	 hours.	 Untreated	 controls	 were	
included	at	each	time	point	as	well	as	at	0	hours.	SF	treatment	significantly	increased	




hours	 (2.7-fold,	 p	 <	 0.05)	 in	 these	 cells.	 Both	 TBX2	 and	 TBX3	 mRNA	 remained	
elevated	at	24	hours,	 albeit	not	 significantly.	 In	CaSki	 cells,	 SF	 treatment	elicited	a	
similar	 response	 with	 regards	 to	 TBX3	 regulation,	 with	 significantly	 increased	
expression	observed	at	2	and	4	hours	post	treatment	(5.4-fold,	p	<	0.01;	4.8-fold,	p	<	
0.0001),	but	with	expression	returning	to	basal	levels	by	24	hours.	TBX2	mRNA	was	







Figure	3.4:	SF	treatment	 increases	TBX2	and	TBX3	expression	in	cervical	cancer	cell	 lines	in	a	cell	 line-
dependent	manner.		
HeLa	 (a),	CaSki	 (b)	and	C-33	A	 (c)	cervical	 cancer	 cell	 lines	were	cultured	 in	60	mm	dishes	 for	24	hours	
after	 seeding.	 Thereafter	 they	 were	 washed	 in	 PBS	 and	 serum	 starved	 overnight.	 The	 cells	 were	 then	
washed	 again	 and	 fresh	 starving	media	 was	 added	 to	 each	 dish.	 Experimental	 dishes	 received	 seminal	
fluid	 (SF)	 in	 the	 media	 (1:50	 final	 concentration)	 while	 control	 dishes	 were	 left	 untreated.	 Cells	 were	
harvested	 by	 scraping	 and	 RNA	 was	 isolated,	 reverse	 transcribed	 and	 TBX2	 and	 TBX3	 mRNA	 was	


































































C-33 A TBX3 mRNA Expression
































TBX2 mRNA undetectable 
in CaSki cells








































































To	 confirm	 that	 SF-mediated	 TBX2	 and	 TBX3	mRNA	 upregulation	 occurred	 at	 the	
transcriptional	level,	HeLa	cells	were	pre-incubated	with	Act	D,	a	potent	repressor	of	
de	novo	mRNA	 transcription,	prior	 to	 treatment	with	SF.	 SF	was	 then	added	drop-
wise	to	treatment	dishes	without	replacement	of	 the	Act	D-containing	media.	 If	SF	
treatment	 does	 induce	 increased	 transcription	 of	 TBX3	 in	 HeLa	 cells,	 no	 response	




on	 HeLa	 cells,	 indicating	 that	 SF	 treatment	 transcriptionally	 regulates	 TBX3	
expression.	 TBX2	expression	was	not	 induced	by	 SF	 treatment	 in	both	 vehicle	 and	
Act	D-treated	cells	(data	not	shown),	making	it	impossible	to	determine	whether	SF	












































and	 serum	 starved	 overnight.	 Thereafter	 they	 were	 washed	 again	 and	 fresh	 starving	 media	 was	
added.	Dishes	were	pre-treated	with	Actinomycin	D	(Act	D,	5	µg	/	mL)	or	with	vehicle	(Veh,	DMSO)	
for	 1	 hour.	One	 dish	 in	 each	 group	was	 further	 treated	with	 SF	 (1:50	 final	 concentration)	 and	 the	
other	left	otherwise	untreated	for	4	hours.	Thereafter	cells	were	harvested	by	scraping	and	RNA	was	
isolated,	reverse	transcribed	and	TBX3	mRNA	was	quantified	by	relative	quantitation.	Data	represents	
the	 pooled	means	 from	 3	 independent	 experiments.	 Treatment	 groups	were	 assessed	 in	 triplicate	






HeLa	 and	 CaSki	 cells	 relative	 to	 their	 respective	 untreated	 controls	 (Figure	 3.4),	 it	










subsequent	 experiment	 that	 included	 additional	 time	 points	 it	 was	 revealed	 that	
TBX3	 protein	 is	 indeed	 detectable	 in	 untreated	 HeLa	 cells.	 Furthermore,	 SF	






















lysates	 were	 used	 as	 TBX2	 positive	 controls.	 TBX3	 expression	 in	 b	 was	 quantified	 via	 relative	







Owing	 to	 its	 primary	 role	 as	 a	 transcription	 factor,	 TBX3	 upregulation	 is	 likely	 to	
result	in	differential	gene	transcription	of	downstream	target	genes.	Therefore,	well-
established	cancer-related	TBX3	target	genes	were	selected	for	investigation,	namely	










p21	 mRNA	 expression	 was	 significantly	 increased	 in	 HeLa	 cells	 treated	 with	 SF	
compared	to	untreated	controls	 (Figure	3.7	a);	a	statistically	significant	 increase	of	
~3.5-fold	was	observed	4	hours	after	SF	addition	(p	<	0.01).	Furthermore,	a	general	
trend	 of	 increased	 mRNA	 expression	 was	 also	 observed	 in	 SF-treated	 CaSki	 cells	
(figure	3.7	b),	thus	indicating	that	this	effect	does	not	exclusively	occur	in	HeLa	cells.	
Additionally,	SF	treatment	also	increased	HeLa	cell	p21	protein	expression	relative	to	
untreated	 controls	 at	 2	 and	 4	 hours	 in	 a	 western	 blot	 experiment	 (Figure	 3.7	 c).	











HeLa	 (a)	 and	 CaSki	 (b)	 cervical	 cancer	 cell	 lines	 were	 cultured	 in	 60	mm	dishes	 for	 24	 hours	 after	
seeding.	Thereafter	they	were	washed	in	PBS	and	serum	starved	overnight.	Cells	were	then	washed	





Each	 graph	 represents	 the	 pooled	 means	 from	 3	 independent	 experiments.	 Time	 points	 were	
assessed	 in	triplicate	within	each	experiment.	Means	±	SEM	are	displayed.	Normal	Two-way	ANOVA	
and	 Šídák’s	 multiple	 comparison	 post-hoc	 tests	 were	 used	 to	 determine	 statistical	 significance.		
**	=	p	<	0.01.	
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upregulation	 of	 p21	 mRNA	 expression	 in	 HeLa	 cells	 occurred	 via	 a	 TBX3-related	
pathway.	Cells	were	 transiently	 transfected	with	 siRNA	 targeting	TBX3	 	 (siTBX3)	or	
with	scrambled	siRNA	sequences	as	a	control	(siCtrl)	and	then	treated	with	SF	(1:50	
final	 concentration)	 for	 4	 hours.	 siTBX3	 HeLa	 cells	 treated	 with	 SF	 expressed	
significantly	 less	 TBX3	mRNA	 than	 SF-treated	 siCtrl	 cells	 (~30%	 of	 siCtrl,	 p<	 0.05),	
indicating	successful	knockdown	of	TBX3	(Figure	3.8).	The	result	of	TBX3	knockdown	
on	p21	expression,	 also	 shown	 in	 Figure	 3.8,	 indicates	 that	 SF-treated	 siTBX3	 cells	
express	 significantly	 less	 p21	 mRNA	 expression	 relative	 to	 SF-treated	 siCtrl	 cells	
(~50%,	p	<	0.01).	Therefore	TBX3	mRNA	is	not	upregulated	by	SF	treatment	in	siTBX3	






either	 an	 siRNA	 targeting	 TBX3	 (siTBX3)	 or	 a	 scrambled	 siRNA	 sequence	 (siCtrl)	 and	 cultured	
overnight.	They	were	then	washed	in	PBS	and	serum	starved	overnight.	Cells	were	washed	again	and	
fresh	starving	media	was	added	to	each	dish.	Experimental	dishes	received	seminal	 fluid	 (SF)	 in	 the	
media	 (1:50	 final	 concentration)	while	 control	 dishes	were	 left	 untreated.	 Cells	were	 treated	 for	 4	
hours,	 after	which	 they	were	harvested	by	 scraping	and	RNA	was	 isolated,	 reverse	 transcribed	and	
TBX3	and	p21	mRNA	was	quantified	by	relative	quantitation.	This	figure	represents	the	pooled	mean	
data	 from	 3	 independent	 experiments.	 Gene	 expression	 in	 each	 treatment	 group	 was	 assessed	 in	






























































































Collectively,	 our	 results	 thus	 far	 have	 shown	 that	 SF	 treatment	 upregulates	 TBX3	
expression	 and	 through	 it	 p21	 expression	 in	 HeLa	 cells.	 In	 other	 contexts,	 TBX3-
mediated	 regulation	 of	 p21	 alters	 cellular	 proliferation	 (Willmer,	 Cooper,	 et	 al.,	
2016).	 Given	 that	 SF	 has	 previously	 been	 shown	 to	 increase	 the	 rate	 of	 HeLa	 cell	
proliferation	(Sutherland	et	al.,	2012),	we	sought	to	investigate	whether	TBX3	plays	a	
role	 in	 mediating	 this	 pro-proliferative	 regulation.	 SF-treated	 and	 untreated	 HeLa	
cells	 were	 cultured	 overnight	 and	 used	 as	 seeding	 stock	 for	 proliferation	 assays	
wherein	cells	were	allowed	 to	proliferate	 for	 set	periods	 (1-7	days)	of	 time	before	
being	counted.	The	results,	displayed	in	Figure	3.9,	indicated	that	while	a	slight	trend	
of	 an	 increased	 growth	 rate	 may	 be	 evident	 in	 SF-treated	 cells,	 no	 statistically	










trypsinisation	and	 counted	at	1,	 3,	 5	 and	7	days	 to	assess	population	growth.	All	 populations	were	































Because	 SF	 treatment	 did	 not	 significantly	 affect	 HeLa	 cell	 proliferation	 despite	
significant	 induction	of	TBX3-mediated	p21	expression,	we	 turned	our	attention	 to	
other	aspects	of	cell	physiology.	We	hypothesized	that	SF-mediated	upregulation	of	
TBX3	might	result	in	decreased	cell	migratory	ability	as	TBX3	overexpression	does	in	
fibrosarcoma	 cells	 (Willmer,	 Cooper,	 et	 al.,	 2016).	 If	 high	 TBX3	 levels	 do	 reduce	
cervical	 cancer	 cell	migration	 rates,	 this	 effect	might	 contribute	 to	 the	mechanism	
underlying	the	observation	that	high	levels	of	TBX3	mRNA	expression	are	associated	
with	 decreased	 lymph	 node	metastasis	 in	 cervical	 carcinomas	 (Lyng	 et	 al.,	 2006).	






to	24	hours	post-wound	creation.	 The	absence	of	a	 treatment	effect	 in	our	assays	
precluded	 investigation	 into	the	role	of	TBX3	 in	HeLa	cell	migration.	Therefore,	the	














remaining	 cells	 were	 incubated	 in	 media	 containing	 mitomycin	 C	 (10	 µg/mL).	 Cells	 were	 further	
treated	with	1:50	SF	 (final	concentration)	 (black	bars)	or	 left	otherwise	untreated	(white	bars).	 Each	




with	 the	number	of	 replicates	specified	above	each	time	point.	b	Displays	a	representative	 series	of	






effects	 of	 SF	 on	 cancerous	 cervical	 tissue.	 Given	 that	 neither	 TBX2	 nor	 TBX3	 are	
universally	 expressed	 in	 all	 adult	 tissues,	 we	 initially	 investigated	 the	 expression	
statuses	 of	 these	 proteins	 in	 cervical	 tissues.	 TBX2	 protein	 is	 overexpressed	 in	




immunohistochemical	 analyses	 (Figure	 3.1)	 showed	 that	 TBX3	 protein	 is	 indeed	
overexpressed	 in	 both	 cervical	 adenocarcinoma	 and	 squamous	 cell	 carcinomas	
compared	 to	 normal	 cervical	 tissue	 samples,	 which	 exhibited	 little	 to	 no	 staining.	
Furthermore,	 adenocarcinoma	and	 squamous	 cell	 carcinoma	 tissues	 also	 exhibited	
significant	overexpression	relative	to	matched	adjacent	normal	cervical	tissues	from	
the	 same	 sections	 (Figure	 3.2).	 These	 results	 indicate	 that	 TBX3	 expression	 is	
overexpressed	 in	 cancerous	 cervical	 tissues.	 Lyng	 et	 al.	 (2006)	 showed	 that	
decreased	TBX3	mRNA	expression	 is	an	 independent	prognostic	predictor	of	 lymph	
node	 metastasis.	 High	 TBX3	 expression	 formed	 part	 of	 a	 gene	 expression	 cluster	
associated	 with	 significantly	 improved	 progression-free	 survival.	 This	 cluster	 was	
associated	 with	 increased	 tumour	 volume	 and	 the	 composition	 thereof	 implied	 a	
pro-proliferative	 role.	 Collectively,	 these	 results	 imply	 that	 TBX3	 expression	 is	








How	 TBX3	 would	 mediate	 an	 effect	 in	 cervical	 cancer	 is	 unclear.	 Our	 analyses	
identified	 positive	 staining	 in	 cancer	 cell	 nuclei	 and	 cytoplasm,	 as	 well	 as	 cases	
where	 cytoplasmic	 staining	was	 high	 and	nuclear	 staining	was	 absent	 (Figure	 3.3).	
TBX3	is	known	to	localize	in	both	cellular	compartments	and	its	distribution	varies	by	
cell	cycle	stage	in	SW1353	chondrosarcoma	cells,	where	its	presence	is	important	for	
progression	 from	 S	 phase,	when	 it	 is	 predominantly	 located	 in	 the	 nucleus,	 to	G2	
(Willmer	 et	 al.,	 2015).	 A	 similar	 cell	 cycle-regulated	 localization	may	be	present	 in	
cervical	cancer	cells,	wherein	TBX3	only	exerts	its	effects	in	certain	phases.	Given	its	
primary	role	as	a	transcription	factor,	it	is	tempting	to	conclude	that	its	influence	on	
gene	 expression	 is	 the	 sole	 mechanism	 whereby	 it	 contributes	 to	 oncogenesis.	
However,	 TBX3	 has	 been	 shown	 to	 regulate	 mRNA	 splicing	 in	 vivo	 (Kumar	 et	 al.,	
2014).	Altered	splicing	patterns	significantly	contribute	to	oncogenic	phenotypes	in	a	




are	 overexpressed	 in	 primary	 cancerous	 cervical	 tissues.	 However,	 their	 apparent	
functions	 in	 these	 tissues	 remained	 to	be	elucidated.	Given	 their	 frequent	 roles	as	
terminal	 effectors	 of	 signaling	 pathways	 (see	 section	 1.3.3),	we	hypothesized	 they	
may	mediate	some	of	the	effects	exerted	by	SF	on	cervical	tissues.	To	determine	if	
this	was	the	case,	we	treated	three	cervical	cancer	cell	lines	with	SF	and	assessed	the	
expression	 patterns	 of	 TBX2	 and	 TBX3	mRNA	 and	 protein	 (Figure	 3.4,	 Figure	 3.6).	
Two	cell	 lines,	HeLa	and	CaSki,	showed	responses	to	treatment	in	this	regard.	TBX3	
mRNA	 and	 protein	 expression	 were	 both	 reliably	 upregulated	 in	 both	 cell	 lines	
following	 treatment	 and	 expression	 was	 also	 detected	 in	 untreated	 cells	 of	 both	
lines.	 Furthermore,	 we	 showed	 that	 this	 increased	 expression	 is	 transcriptionally	
regulated	 in	HeLa	 cells	 (Figure	3.5).	While	basal	 TBX3	protein	expression	has	been	
reported	for	both	cell	lines	in	existing	literature	(Mowla	et	al.,	2011;	Burgucu	et	al.,	
2012),	our	 finding	 that	SF	 increases	TBX3	expression	 in	HeLa	and	CaSki	 cell	 lines	 is	
novel.	Given	that	HeLa	cells	are	derived	from	an	adenocarcinoma	whereas	CaSki	cells	
originate	 from	a	squamous	cell	 carcinoma,	TBX3	expression	does	not	appear	 to	be	
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limited	to	a	particular	cervical	cancer	subtype.	This	finding	is	in	agreement	with	our	
in	 vivo	 investigations,	 which	 showed	 that	 both	 squamous	 cell	 carcinoma	 and	
adenocarcinoma	tissues	significantly	overexpress	TBX3	protein	compared	to	normal	
tissue,	 as	 discussed	 above.	 Furthermore,	 our	 results	 indicate	 that	 SF	 is	 capable	 of	
inducing	increased	expression	in	both	subtypes.	
	TBX2	mRNA	was	 detectable	 in	HeLa,	 but	 not	 CaSki,	 cells	 (Figure	 3.4).	While	 TBX2	






has	 investigated	 TBX2	mRNA	expression	 or	 the	 effects	 of	 SF	 treatment	 thereon	 in	
HeLa	or	CaSki	cells.	The	contradiction	in	our	observations	that	TBX2	mRNA	is	present	
and	regulated	by	SF	in	HeLa	cells	while	TBX2	protein	remains	undetectable	in	treated	
or	 untreated	 cells	 is	 puzzling.	 Despite	 being	 reliably	 detectable	 in	 multiple	
independent	 time	 point	 experiments	 (Figure	 3.4),	 TBX2	mRNA	 expression	was	 not	
increased	by	 SF	 in	Act	D	 treatment	 experiments	 in	 either	 vehicle	 or	Act	D-treated	
cells	 (data	 not	 shown).	 The	 lack	 of	 TBX2	 induction	 in	 these	 experiments	 was	
surprising	 and	 precluded	 assessment	 of	 the	 impact	 of	 Act	 D	 treatment	 on	 TBX2	
mRNA	 expression.	 We	 can	 therefore	 offer	 no	 explanation	 for	 the	 apparent	
disconnect	 between	 TBX2	 mRNA	 and	 protein	 expression	 observed	 in	 our	
experiments.	 The	 duration	 of	 storage	 of	 SF	might	 explain	 the	 lack	 of	 TBX2	mRNA	
induction	 in	Act	D	experiments.	 It	may	be	that	 the	component(s)	of	SF	responsible	
for	 TBX2	 induction	 degrade	 more	 rapidly	 than	 those	 influencing	 TBX3	 (which	
continued	 to	 be	 reliably	 inducible	 in	 all	 experiments),	 even	when	 SF	 is	 stored	 at	 -
80°C.	 Given	 that	 a	 second,	 recently	 collected	 pool	 of	 SF	 was	 also	 able	 to	 induce	
increased	TBX2	mRNA	expression	(data	not	shown),	the	relative	age	of	SF	seems	to	





(Figure	 3.4).	 However,	 expression	 of	 either	 was	 unaffected	 by	 SF	 treatment,	 thus	
implying	that	context	dependent	factors	are	required	for	SF-mediated	upregulation	
of	 these	 genes.	 Interestingly,	 C-33	A	 cells	 have	 tested	 negative	 for	 both	HPV	DNA	
and	 RNA	 in	 tests	 conducted	 by	 the	 ATCC,	whereas	 both	HeLa	 and	 CaSki	 cells	 test	
positive.	 Research	 by	 Schneider	 et	 al.	 (2013)	 has	 shown	 that	 TBX2	 and	 TBX3	 are	
capable	 of	 interacting	 with	 the	 HPV16	 L2	 capsid	 protein.	 Furthermore,	 TBX2	 and	
TBX3	were	 shown	 to	 repress	 the	HPV	 promoter	 region	 known	 as	 the	 long	 control	
region	of	a	number	of	HPV	strains.	This	repression	was	significantly	enhanced	by	the	
presence	of	L2.	TBX2	and	HPV	L2	were	shown	to	colocalise	in	primary	CIN	1	and	-2	
tissue	 samples.	 Other	 research	 has	 also	 shown	 that	 TBX2	 protein	 expression	 in	
squamous	 cell	 carcinomas	 is	 significantly	 associated	with	HPV16	 E7	detection	 (Liu,	
Jiang	 &	 Zhang,	 2010b).	 Clearly,	 interactions	 between	 these	 TBX	 proteins	 and	 HPV	
proteins	 and	 genomes	 exist;	 while	 further	 research	would	 be	 required	 to	 confirm	
any	direct	 association,	 it	 is	 possible	 that	 SF-mediated	TBX2	and	TBX3	upregulation	
may	be	in	some	way	dependent	on	the	presence	of	HPV.	
While	 a	 clear	 effect	 of	 SF	 treatment	 on	 TBX3	 gene	 and	 protein	 expression	 was	
observed,	 the	 functional	 significance	 of	 this	 effect	 remained	 to	 be	 established.	
Therefore,	 we	 turned	 our	 attention	 to	 known	 downstream	 targets	 of	 TBX3’s	
transcription	 factor	 activity,	 namely	 PTEN	 and	 p21.	 TBX3	 has	 been	 inversely	
correlated	with	PTEN	expression	in	previous	work	on	head	and	neck	squamous	cell	
carcinomas	 (Burgucu	 et	 al.,	 2012).	 Given	 that	 these	 cancers	 are	 also	 commonly	
associated	 with	 HPV16	 (as	 well	 as	 other	 oncogenic	 HPV	 subtypes)	 presence	 it	 is	
tempting	 to	 speculate	 that	 similar	 oncogenic	 processes	 may	 be	 found	 in	 cervical	
carcinomas	 (Agalliu	 et	 al.,	 2016).	 Indeed,	 Burgucu	 et	 al.	 (2012)	 showed	 that	
overexpression	 of	 TBX3	 in	 HeLa	 cells	 resulted	 in	 repression	 of	 both	 basal	 and	
induced	endogenous	PTEN	expression.	However,	PTEN	mRNA	was	unaffected	by	SF	










SF-mediated	 p21	 upregulation	 is	 at	 least	 partially	 mediated	 via	 a	 TBX3-related	
pathway	(Figure	3.8).	In	the	majority	of	cases,	TBX3	has	been	shown	to	repress	p21	
either	directly	or	 indirectly	 (Peres	&	Prince,	2013;	Willmer,	Hare,	et	al.,	2016).	Yet,	
recent	work	 from	 our	 laboratory	 has	 shown	 that	 TBX3	 is	 capable	 of	 inducing	 p21	
expression	in	HT1080	fibrosarcoma	cells	(Willmer,	Cooper,	et	al.,	2016).	The	role	of	
TBX3	in	this	context	is	oncoprotective,	whereas	the	majority	of	SF	studies	using	HeLa	
cells	 have	 shown	 that	 treatment	 induces	 oncogenic	 changes	 (see	 section	 1.6).	
However,	 it	 cannot	 be	 assumed	 that	 TBX3-mediated	 increases	 in	 p21	 will	 always	
have	 protective	 consequences.	 Indeed,	 overexpression	 of	 p21	 is	 correlated	 with	
poor	prognostic	outcomes	in	a	number	of	cancers,	including	cervical	cancers,	where	
its	 expression	 levels	 correlate	with	 tumour	 stage	 (Bae	 et	 al.,	 2001;	 Cheung	 et	 al.,	
2001;	 reviewd	 in	 Abbas	&	Dutta,	 2009).	 The	 importance	 of	 this	 SF-induced,	 TBX3-
mediated	upregulation	of	p21	expression	therefore	remains	to	be	elucidated.		
	
TBX3	 and	 its	 interactions	 with	 p21	 frequently	 result	 in	 altered	 rates	 of	 cell	
proliferation.	TBX3-mediated	repression	of	p21	is	required	for	increased	rates	of	cell	
proliferation	 in	 chondrosarcoma	 cell	 lines,	 and	 TBX3’s	 ability	 to	 promote	
proliferation	 in	 mammary	 epithelial	 and	 hepatic	 progenitor	 cells	 is	 inversely	
correlated	with	p21	expression	(Platonova	et	al.,	2007;	Suzuki	et	al.,	2008;	Willmer,	
Cooper,	 et	 al.,	 2016;	 Willmer,	 Hare,	 et	 al.,	 2016).	 Furthermore,	 when	 acting	
oncoprotectively	 in	 HT1080	 fibrosarcomas,	 TBX3’s	 induction	 of	 p21	 expression	
decreases	cell	proliferation	 relative	 to	cells	 in	which	TBX3	has	been	knocked	down	
(Willmer,	 Cooper,	 et	 al.,	 2016).	 We	 therefore	 set	 out	 to	 investigate	 whether	 SF-
mediated	 TBX3	 upregulation	 and	 the	 consequent	 increase	 in	 p21	 expression	
influences	 HeLa	 cell	 proliferation.	 This	 would	 be	 investigated	 by	 comparing	 the	
proliferative	rate	of	SF-treated	HeLa	cells	with	that	of	SF-treated	HeLa	cells	in	which	
TBX3	was	knocked	down.	Our	results,	however,	indicated	no	significant	difference	in	




SF	 induces	 increased	 rates	 of	 HeLa	 cell	 proliferation,	 both	 in	 vitro	 and	 in	 mouse	
xenograft	 experiments	 (Liu	 et	 al.,	 2011;	 Sutherland	 et	 al.,	 2012).	 The	 discrepancy	
between	 our	 results	 and	 those	 in	 existing	 literature	 could	 be	 accounted	 for	 by	
several	factors.	Given	the	heterogeneous	nature	of	SF,	the	pool	of	samples	used	in	
this	study	may	lack	the	pro-proliferative	induction	ability	observed	in	other	studies.	
Alternatively,	methodological	 differences	may	be	 involved.	 The	 in	 vitro	 findings	by	
Sutherland	 et	 al.	 (2012)	 were	 established	 by	 ki67	 expression	 assays,	 wherein	
expression	 levels	 were	 measured	 after	 6	 hours	 of	 incubation	 with	 SF.	 Our	 study	
assessed	growth	by	physical	counting	of	cells	over	much	longer	periods	and	assessed	
pre-treatment,	 rather	 than	 constant	 incubation.	Nonetheless,	 owing	 to	 the	 lack	 of	
increased	proliferation	in	SF-treated	HeLa	cells	in	our	study,	we	could	not	determine	
a	role	for	TBX3	or	p21	in	SF-mediated	HeLa	cell	proliferation.	






play	 a	 role	 therein.	 SF	 treatment	 failed	 to	 induce	 changes	 in	 the	 rate	 of	 cellular	
migration	in	our	experiments	(Figure	3.10).	However,	given	the	nature	of	our	assays,	
we	 can	 only	 conclude	 that	 SF	 treatment	 does	 not	 increase	 the	 overall	motility	 of	
HeLa	cells.	We	cannot	discount	whether	it	may	increase	directional	migration,	which	
might	be	observed	in	transwell	assays	where	only	one	compartment	contains	SF,	nor	






	This	 study	 has	 several	 limitations.	 Firstly,	 the	 sample	 size	 of	 our	
immunohistochemical	 analysis	 was	 relatively	 small	 and	 requires	 replication	 in	 a	
larger	study.	As	a	consequence	of	the	small	size,	no	stratification	by	tumour	stage,	
patient	 age,	 or	 other	 clinical	 variables	 could	 be	 made.	 Furthermore,	 some	
nonspecific	staining	was	also	observed	in	the	stromal	extracellular	matrix,	especially	
in	 low-staining	 normal	 tissues	 (Figure	 3.3),	 or	 in	 highly	 necrotic	 cancerous	 tissues	
(not	 shown),	 indicating	 that	 current	 protocols	 could	 be	 optimized	 for	 these	 tissue	
types.		Secondly,	while	we	established	that	SF	treatment	does	indeed	influence	TBX3	
expression	 in	 two	 cell	 lines	 as	 well	 as	 TBX2	 mRNA	 expression	 in	 HeLa	 cells,	 the	
discrepancy	 between	 this	 finding	 and	 the	 lack	 of	 TBX2	 protein	 as	 well	 as	 mRNA	
expression	 in	 later	 experiments	 remains	 to	 be	 explained.	 Thirdly,	 we	 have	 yet	 to	
identify	 the	mechanism	whereby	SF	mediates	 this	upregulation	beyond	confirming	
that	it	is	transcriptional.	Finally,	we	could	not	establish	the	functional	significance	of	




This	 study	 has	 presented	 the	 novel	 finding	 that	 TBX3	 protein	 is	 overexpressed	 in	
both	 cervical	 squamous	 cell	 carcinomas	 and	 adenocarcinomas	 relative	 to	 normal	
cervical	epithelium.	 In	an	 in	vitro	context,	we	 found	that	SF	 is	able	 to	 increase	 the	
expression	of	TBX2	mRNA,	but	not	protein,	only	in	HeLa	cells	and	was	able	to	induce	
TBX3	mRNA	and	protein	expression	 in	HeLa	and	CaSki	cells	but	not	 in	C-33	A	cells.	
We	 also	 established	 that	 this	 effect	 was	 mediated	 at	 the	 transcriptional	 level.	
Furthermore,	 the	 resultant	 increase	 in	 TBX3	 expression	 selectively	 influenced	 the	
expression	of	known	target	genes,	and	we	report	the	second	instance	wherein	TBX3	
is	 shown	to	 increase	p21	expression	 rather	 than	 repress	 it.	While	we	were	able	 to	
demonstrate	that	SF-mediated	upregulation	of	p21	was	at	least	partially	dependent	




















































































































































































































































































































































































































































































































































































































































































































INSTITUTE OF INFECTIOUS DISEASE AND MOLECULAR MEDICINE 
Wernher and Beit North 
Faculty of Health Sciences 
Anzio Road, Observatory 
Tel: (+27) 21 406 6268 
Fax: (+27) 21 406 6061 
E-Mail: arieh.katz@uct.ac.za
Patients Information Sheet and  
Seminal Fluid Collection Consent Form 
Role of seminal fluid and inflammatory pathways/agents on cervical 
cancer progression and HIV infection, UCT HREC REF: 0849/2015  
Why is this study being done? 
Cervical cancer is one of the leading causes of cancer-related deaths in 
women. The prevalence of this disease is particularly high in South Africa. This 
research study is aimed at investigating the biological process responsible for 
the development and progression of cervical cancer.  
HIV/Aids is also a big health problem in Africa and the world. We still do not 
know everything about how HIV infects people. 
There is evidence implicating seminal fluid (the fluid of a mans ejaculate, 
without the sperm) may play a role in how infective HIV is in women. There is 
also evidence that it may play a role in cervical cancer formation or progression. 
The study will investigate role of seminal fluid on HIV infection and cervical 
cancer. 
Why are you being asked to take part? 
As a patient of the Groote Schuur Fertility clinic, you are already providing a 
semen sample today as part of your medical treatment. Once the clinic has 
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analysed your sample, we would like to use the what’s left over for our study. 
You don’t need to contribute anything more than you already would have done 
today. 
How many people will take part in the study? 
A total of 100 men will take part in this study. 
How long will the study last? 
The study will last until we have used all of the seminal fluid, or for one year. 
What do we do to decide if you are eligible to be taking part? 
To be eligible, you must have healthy semen. A technician at the Groote 
Schuur Hospital Fertility Clinic will confirm that your semen is healthy according 
to World Health Organisation guidelines. 
What will happen if you decide to take part in the study? 
You will be asked to sign an informed consent form. Once the fertility clinic is 
done with your semen sample that was provided today, we will receive it from 
them. We receive them in numbered tubes. There is no way of knowing whose 
is whose once we collect them. 
What are the risks and discomforts of this study? 
There are no risks or discomforts to you if you participate in this study. 
Are there any benefits to you for being in the study? 
Other than contributing to the advancement of scientific research, there are no 
benefits to participating in this study. 
What other choices do you have? 
You may choose to not take part in our study. Your choice to participate or not 
will have no influence on your future treatment at this or any other hospital. 
What will happen when the study is over? 
The research will be analysed and presented as part of one or more theses for 
degree purposes. The results may be used in academic publications. 
89	
Will your test results be shared with you? 
We will not produce results that are relevant to you as a patient. No results will 
be shared with you directly. 
Will the results of the research be shared with you? 
We will not share the results of our research with you directly. However, 
university theses and journal publications resulting from the research will be 
available to the public. 
Will any of your blood, tissue or other samples be stored and used for 
research in the future? 
Your semen sample will be stored until it is used, or for one year after 
collection. 
Will you receive any reward (money or food vouchers) for taking part in 
this study? 
There are no rewards for participating in this study. 
Who will see the information that is collected about you during the study? 
We will not collect personal information about you during this study. 
Who do I speak to (or contact) if I have any questions about the study? 
You are encouraged to discuss any worries or issues you may have with the 
investigators of this project.   
If you have any questions regarding this study, please do not hesitate to contact 
us at any time at the numbers listed below: 
Professor Arieh Katz, Division of Medical Biochemistry, Faculty of Health 
Sciences, UCT, Tel: 021-4066268, email: arieh.katz@uct.ac.za 
In addition, in case you have any ethical concerns or questions about your rights 
or welfare as a participant on this research study, UCT’s Faculty of Health 
Sciences “Human Research Ethics Committee” can be contacted on 021 406 
6338, email: shuretta.thomas@uct.ac.za  
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CONSENT FORM 
I am consenting to participate in the study entitled: Role of seminal fluid and 
inflammatory pathways/agents on cervical cancer progression and HIV 
infection (UCT HREC REF: 0849/2015).  
I have read (or have read to me) the consent form. I understand, that I will be 
included in this study, the effect of which has been explained to me by 
_____________________ 
I am aware that the remainder of the semen sample that I provide today will be 
will be taken for purposes of this study. I voluntarily agree to participate in the 
study without any coercion.  I also know that should I change my mind about 
participating in the study, I may do so without compromising my future prospects 
of treatment or care.  
Name of patient: ____________________________ 
Signature of patient: ____________________________  
The above signed this consent form in my presence and appears to understand it. 

































































PPIA	 CC-CACCGTGTTCTTCGACAT1 60.32	 CCAGTGCTCAGAGCACGAAA	 60.66	 116/2732
HPRT1	 TGAGGATTTGGAAAGGGTGTT	 57.39	 CAGAGGGCTACAATGTGATGG	 58.43	 111	
EEF1A1	 TGCGGTGGGTGTCATCAAA	 59.85	 AAGAGTGGGGTGGCAGGTATT3	 61.12	 123	
HSPC90	
AB1	
ATGGAAGAGAGCAAGGCAAA	 57.41	 AATGCAGCAAGGTGAAGACA	 58.01	 117	




	 Cannot	 discriminate	 between	 PPIA	 mRNA	 transcript	 variants	 1	 and	 2,	 thus	 producing	 two	 amplicons
3





Figure	 S3:	 Example	 of	 primer	 dimers	 present	 in	 a	 melt	 curve	 from	 a	 failed	
amplification.	
Primer	dimers	in	experimental	reactions	are	indicated	by	the	blue	arrow.	
Nonspecific	amplification	in	no-template	controls	is	indicated	by	the	purple	arrow.	
95	
Figure	S4:	Example	of	genomic	contamination	present	in	a	melt	curve	from	a	failed	
amplification.	
Contamination	indicated	by	blue	arrow.	
